Red White & Bloom Brands (RWBYF) 20-F 12 Dec 19 2019 FY Annual report (foreign) Financial data

Document and Entity Information

Document and Entity Information	12 Months Ended
	Jul. 31, 2019shares
Details
Registrant CIK	0001744345
Fiscal Year End	--07-31
Registrant Name	Tidal Royalty Corp.
SEC Form	20-F
Period End date	Jul. 31, 2019
Number of common stock shares outstanding	292,607,662
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Voluntary filer	No
Well-known Seasoned Issuer	No
Shell Company	false
Emerging Growth Company	false
Document Period Start Date	Aug. 1, 2018
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	789 West Pender Street
Entity Address, Address Line Two	Suite 810
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Country	CA
Entity Address, Postal Zip Code	V6C 1H2
Entity Address, Address Description	Address of principal executive offices
Contact Personnel Name	Theo van der Linde
Contact Personnel Email Address	Theo@pashleth.com
Entity File Number	000-55992
Document Registration Statement	false
Document Accounting Standard	International Financial Reporting Standards
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY

Consolidated Statements of Fina

Consolidated Statements of Financial Position - CAD ($)		Jul. 31, 2019	Jul. 31, 2018
CURRENT ASSETS
Cash and cash equivalents		$ 2,961,514	$ 33,904,759
Sales tax receivable		0	129,415
Convertible debenture receivable	[1]	15,000,000	0
Prepaid expenses and deposits	[2]	129,418	531,859
Current assets		18,090,932	34,566,033
Deposits		328,700	0
Promissory note receivable	[3]	3,412,421	0
Land	[4]	592,655	0
Investments in equity securities	[5]	1,766,953	0
TOTAL ASSETS		24,191,661	34,566,033
CURRENT LIABILITIES
Accounts payable and accrued liabilities	[6]	336,540	311,357
Due to related parties	[7]	21,347	18,685
Loans payable		0	10,000
TOTAL LIABILITIES		357,887	340,042
EQUITY
Convertible preferred shares	[8]	2,388,941	1,754,721
Convertible preferred shares issuable	[8]	0	2,000,000
Common shares	[8]	48,525,793	45,432,573
Reserves	[8]	11,816,876	5,324,016
Accumulated other comprehensive loss		(796)	0
Accumulated deficit		(38,897,040)	(20,285,319)
TOTAL EQUITY		23,833,774	34,225,991
TOTAL LIABILITIES AND EQUITY		$ 24,191,661	$ 34,566,033
[1]	See Note 5.
[2]	See Note 4.
[3]	See Note 6.
[4]	See Note 7.
[5]	See Note 8.
[6]	See Note 9.
[7]	See Note 10.
[8]	See Note 11.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - CAD ($)		12 Months Ended
		Jul. 31, 2019	Jul. 31, 2018
Expenses
Consulting fees	[1]	$ 1,333,704	$ 1,933,550
General and administration		223,985	93,861
Investor relations and stock promotion		2,521,416	1,196,309
Insurance		135,493	0
Professional fees		1,100,143	461,195
Rent	[1]	195,050	84,670
Share-based compensation	[2]	7,329,800	3,250,476
Salaries and benefits	[1]	915,585	244,526
Transfer agent and filing fees		88,215	76,869
Travel		131,552	106,368
Operating Expenses		(13,974,943)	(7,447,824)
Other income (expense)
Dividends income		2,467	0
Foreign exchange gain (loss)		260,880	(377,265)
Gain on debt extinguishment		10,000	0
Interest income		404,921	0
Realized gain on investments in equity securities and convertible debentures	[3]	281,892	0
Unrealized loss on investments in equity securities	[4]	(5,373,032)	0
Write down of sales tax receivable		(223,906)	0
Net loss		(18,611,721)	(7,825,089)
Other comprehensive loss
Foreign subsidiary currency translation loss		(796)	0
Net loss and comprehensive loss for the year		$ (18,612,517)	$ (7,825,089)
Loss per share, basic and diluted for the year		$ (0.07)	$ (0.26)
Weighted average number of common shares outstanding		271,055,333	30,039,081
[1]	See Note 10.
[2]	See Notes 10 and 11.
[3]	See Notes 5 and 8.
[4]	See Note 8.

Consolidated Statements of Chan

Consolidated Statements of Changes in Equity (Deficiency) - CAD ($)	Convertible preferred shares	Convertible preferred shares issuable	Common Stock	Share-based payment reserve	Warrant reserve	Total reserves $	Retained Earnings	AOCI Attributable to Parent	Total
Equity Balance, Starting at Jul. 31, 2017	$ 0		$ 12,297,109	$ 27,464	$ 0	$ 27,464	$ (12,460,230)	$ 0	$ (135,657)
Shares Outstanding, Starting at Jul. 31, 2017	0		2,843,636
Stock Issued During Period, Value, New Issues	$ 2,000,000	$ 0	$ 0	0	0	0	0	0	2,000,000
Stock Issued During Period, Shares, New Issues	40,000,000		0
Stock Issued During Period, Value, Stock Options Exercised	$ 0	2,000,000	$ 0	0	0	0	0	0	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0		0
Fair value of preferred shares finders' warrants, Value	$ (141,440)	$ 0	$ 0	$ 0	$ 141,440	$ 141,440	$ 0	$ 0	$ 0
Fair value of preferred shares finders' warrants, Shares	0		0
Issuance of 59,370,000 special warrants, Value	0	0	0	0	2,968,500	2,968,500	0	0	2,968,500
Issuance of 59,370,000 special warrants, Shares	0		0
Issuance of 3,757,000 finders' special warrants, Value	0	0	(187,850)	0	187,850	187,850	0	0	0
Issuance of 3,757,000 finders' special warrants, Shares	0		0
Issuance of 57,120,000 special warrants, Value	0	0	0	0	2,856,000	2,856,000	0	0	2,856,000
Issuance of 57,120,000 special warrants, Shares	0		0
Issuance of 5,292,000 finders' special warrants, Value	0	0	(264,600)	0	264,600	264,600	0	0	0
Issuance of 5,292,000 finders' special warrants, Shares	0		0
Issuance of 12,690,000 special warrants, Value	0	0	0	0	634,500	634,500	0	0	634,500
Issuance of 12,690,000 special warrants, Shares	0		0
Issuance of 1,220,000 finders' special warrants, Value	0	0	(61,000)	0	61,000	61,000	0	0	0
Issuance of 1,220,000 finders' special warrants, Shares	0		0
Conversion of special warrants, Value	0	0	5,824,500	0	(5,824,500)	(5,824,500)	0	0	0
Conversion of special warrants, Shares	0		116,490,000
Conversion of 3,757,000 finders' special warrants, Value	0	0	187,850	0	(187,850)	(187,850)	0	0	0
Conversion of 3,757,000 finders' special warrants, Shares	0		3,757,000
Conversion of 5,292,000 finders' special warrants, Value	0	0	264,600	0	(264,600)	(264,600)	0	0	0
Conversion of 5,292,000 finders' special warrants, Shares	0		5,292,000
Private placements, Value	0	0	31,137,159	0	0	0	0	0	31,137,159
Private placements, Shares	0		94,355,026
Proceeds from warrants exercised, Value	0	0	252,500	0	0	0	0	0	252,500
Proceeds from warrants exercised, Shares	0		5,050,000
Share issuance costs, Value	(103,839)	0	(4,017,695)	0	1,209,136	1,209,136	0	0	(2,912,398)
Share issuance costs, Shares	0		0
Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture	$ 0	$ 0	$ 0	$ 3,250,476	$ 0	$ 3,250,476	$ 0	$ 0	$ 3,250,476
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	0		0
Foreign subsidiary currency translation loss									0
Net Income (Loss)	$ 0	0	$ 0	0	0	0	(7,825,089)	0	(7,825,089)
Shares Outstanding, Ending at Jul. 31, 2018	40,000,000		227,787,662
Equity Balance, Ending at Jul. 31, 2018	$ 1,754,721	2,000,000	$ 45,432,573	3,277,940	2,046,076	5,324,016	(20,285,319)	0	34,225,991
Stock Issued During Period, Value, New Issues	$ 2,000,000	$ (2,000,000)	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Stock Issued During Period, Shares, New Issues	40,000,000		0
Proceeds from warrants exercised, Value	0	0	890,500	0	0	0	0	0	890,500
Proceeds from warrants exercised, Shares	0		17,810,000
Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture	$ 0	$ 0	$ 0	$ 7,329,800	$ 0	$ 7,329,800	$ 0	$ 0	$ 7,329,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	0		0
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ (1,365,780)	$ 0	$ 1,365,780	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Stock Issued During Period, Shares, Conversion of Convertible Securities	(29,100,000)		29,100,000
Conversion of 4,000,000 special finder warrants, Value	0	0	141,440	0	(141,440)	(141,440)	0	0	0
Conversion of 4,000,000 special finder warrants, Shares	0		4,000,000
Conversion of 12,690,000 special warrants, Value	0	0	634,500	0	(634,500)	(634,500)	0	0	0
Conversion of 12,690,000 special warrants, Shares	0		12,690,000
Conversion of 1,220,000 special finder warrants, Value	0	0	61,000	0	(61,000)	(61,000)	0	0	0
Conversion of 1,220,000 special finder warrants, Shares	0		1,220,000
Foreign subsidiary currency translation loss	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ (796)	$ (796)
Net Income (Loss)	$ 0	0	$ 0	0	0	0	(18,611,721)	0	(18,611,721)
Shares Outstanding, Ending at Jul. 31, 2019	50,900,000		292,607,662
Equity Balance, Ending at Jul. 31, 2019	$ 2,388,941	$ 0	$ 48,525,793	$ 10,607,740	$ 1,209,136	$ 11,816,876	$ (38,897,040)	$ (796)	$ 23,833,774

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - CAD ($)		12 Months Ended
		Jul. 31, 2019	Jul. 31, 2018
Net Cash Provided by (Used in) Operating Activities
Net loss for the year		$ (18,611,721)	$ (7,825,089)
Items not affecting operating cash:
Accrued interest		(403,488)	0
Realized gain on investments in equity securities and convertible debentures	[1]	(281,892)	0
Unrealized loss on investments in equity securities	[2]	5,373,032	0
Write down of sales tax receivable		223,906	0
Gain on debt extinguishment		(10,000)	0
Net foreign exchange gain		(64,057)	0
Share-based compensation	[3]	7,329,800	3,250,476
Items not affecting operating cash		(6,444,420)	(4,574,613)
Net changes in non-cash working capital:
Sales tax receivable		(94,491)	(128,557)
Prepaid expenses and deposits		73,739	(530,648)
Accounts payables and accrued liabilities		27,233	206,132
Due to related parties		2,662	0
Net Cash Provided by (Used in) Operating Activities		(6,435,277)	(5,027,686)
FINANCING ACTIVITIES
Due to related parties		0	(4,081)
Shares issued for cash		0	0
Repayment of loan		0	(60,000)
Proceeds from loan		0	40,000
Proceeds from exercise of common share purchase warrants		890,500	252,500
Proceeds from private placement of special warrants		0	6,459,000
Proceeds from issuance of preferred units and exercise of preferred share purchase warrants		0	4,000,000
Proceeds from private placement of common shares		0	31,137,159
Share issuance costs		0	(2,912,398)
Net Cash Provided by (Used in) Financing Activities		890,500	38,912,180
INVESTING ACTIVITIES
Investment in convertible debenture receivable		(15,000,000)	0
Land acquisition		(592,655)	0
Investment in Lighthouse Strategies, LLC		(6,574,000)	0
Investment in Harborside Inc		(3,000,000)	0
Advances for promissory note receivable		(3,216,274)	0
Proceeds from sales of investment in Harborside Inc		2,984,461	0
Net Cash Provided by (Used in) Investing Activities		(25,398,468)	0
Increase (decrease) in cash and cash equivalents		(30,943,245)	33,884,494
Cash and Cash Equivalents, at Carrying Value, Beginning Balance		33,904,759	20,265
Cash and Cash Equivalents, at Carrying Value, Ending Balance		2,961,514	33,904,759
The components of cash and cash equivalents are:
Cash at bank		209,268	33,789,759
Money market funds		2,637,246	0
Term deposit		115,000	115,000
Cash and cash equivalents		2,961,514	33,904,759
Non-cash Investing and Financing Activities
Finders' warrants issued pursuant to private placement		0	1,209,136
Finders' warrants issued pursuant to special warrant issuance		0	513,450
Preferred share finders' warrants		0	141,440
Conversion of preferred shares		1,365,780	0
Conversion of special warrants and special finders warrants		$ 836,940	$ 6,276,950
[1]	See Notes 5 and 8.
[2]	See Note 8.
[3]	See Notes 10 and 11.

1. Nature and Continuance of Op

1. Nature and Continuance of Operations	12 Months Ended
	Jul. 31, 2019
Notes
1. Nature and Continuance of Operations	1. Nature and Continuance of Operations Tidal Royalty Corp. ("the Company") was incorporated under the laws of British Columbia The Company’s principal business is to invest in conventional equity, debt and other forms of investments in private and public companies in Canada and the United States. The head office, address and records office of the Company are located at Suite 810 - 789 West Pender Street , Vancouver , British Columbia, V6C 1H2 . The principal place of business of the Company is 161 Bay St., Suite 4010, Toronto ON, M5J 2S1. On May 13, 2019, the Company entered into a business combination agreement (the “Definitive Agreement”) with MichiCann Medical Inc. (d/b/a Red White & Bloom) (“MichiCann”), with respect to the acquisition of all of the issued and outstanding shares of MichiCann (“Proposed Transaction”). As at November 28, 2019, the transaction has not closed (see Note 16). These consolidated financial statements have been prepared on the basis of accounting principles applicable to a going concern, which assumes the Company will be able to continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. As at July 31, 2019, the Company has an accumulated deficit of $38,897,040 , no source of operating cash flow and no assurance that sufficient funding will be available. Management intends to raise funds through a combination of equity and/or debt financing, along with a realization of sale of investments. The success of these plans will also depend upon the ability of the Company to generate cash flows from its portfolio investments. These consolidated financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary, should the Company be unable to continue as a going concern. Such amounts could be material. However, Management has assessed and concluded that the Company has the ability to continue as a going concern for at least the next twelve months.

2. Basis of Preparation and Sta

2. Basis of Preparation and Statement of Compliance	12 Months Ended
	Jul. 31, 2019
Notes
2. Basis of Preparation and Statement of Compliance	2. Basis of Preparation and Statement of Compliance Statement of Compliance These consolidated financial statements have been prepared in accordance International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board. The consolidated financial statements were approved and authorized for issuance by the Board of Directors on November 28, 2019. Basis of Presentation The consolidated financial statements have been prepared on a historical cost basis except for financial instruments described in Note 3(c), which are measured at fair value. Functional and Presentation Currency These financial statements are presented in Canadian dollars. The functional currency of each entity is determined using the currency of the primary economic environment in which the entity operates. The Company’s functional currency, as determined by management, is the Canadian dollar. The Company’s US subsidiaries functional currencies, as determined by management, are the United States dollar. Basis of Consolidation During the year ended July 31, 2019, the Company incorporated several subsidiaries. As at July 31, 2019, the Company’s structure includes Tidal Royalty Corp., the parent company incorporated pursuant to the laws of the Business Corporations Act (British Columbia), and the following subsidiaries: Entity Domicile of Incorporation % of interest at July 31, 2019 Royalty USA Corp. Delaware , USA 100% RLTY Beverage 1 LLC Delaware , USA 100% RLTY Development MA 1 LLC Delaware , USA 100% RLTY Development 1 NV 1 LLC Delaware , USA 100% RLTY Development Orange LLC Massachusetts , USA 100% RLTY Development Springfield LLC Massachusetts , USA 100% RLTY Service LLC Delaware , USA 100% RLTY Development FLA 1 LLC Delaware , USA 100% RLTY Development FLA 2 LLC Delaware , USA 100% RLTY Development CA 1 LLC Delaware , USA 100% These consolidated financial statements include the accounts of the Company and its controlled entities. Control is achieved when the Company has the power to govern the financial operating policies of an entity so as to obtain benefits from its activities. Subsidiaries are fully consolidated from the date on which control is transferred to the Company until the date on which control ceases. All inter-company transactions, balances, income and expenses are eliminated in full upon consolidation. Use of Estimates and Judgments The preparation of financial statements in accordance with IFRS requires management to make estimates and assumptions about the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities, and the results of operations. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following: Significant accounting estimates: i) Investments in equity securities, convertible and promissory notes receivable Management uses valuation techniques in measuring the fair value of investments in equity securities, convertible and promissory notes receivable. In applying the valuation techniques management makes maximum use of market inputs wherever possible, and uses estimates and assumptions that are, as far as possible, consistent with observable data that market participants would use in pricing the instrument. Where applicable data is not observable, company-specific information is considered when determining whether the fair value of a investment in equity securities or convertible and promissory notes receivable should be adjusted upward or downward at the end of each reporting period. In addition to company-specific information, the Company will take into account trends in general market conditions and the share performance of comparable publicly-traded companies when valuing investment in equity securities, convertible and promissory notes receivable. ii) Share-based payment transactions Management uses the Black-Scholes pricing model to determine the fair value of stock options and standalone share purchase warrants issued. This model requires assumptions of the expected future price volatility of the Company’s common shares, expected life of options and warrants, future risk-free interest rates and the dividend yield of the Company’s common shares. Significant accounting judgements: i) Going concern The assessment of the Company’s ability to continue as a going concern involves management judgement about the Company’s resources and future prospects. ii) Income taxes Management exercises judgment to determine the extent to which deferred tax assets are recoverable, and can therefore be recognized in the statements of financial position and comprehensive income or loss.

3. Significant Accounting Polic

3. Significant Accounting Policies	12 Months Ended
	Jul. 31, 2019
Notes
3. Significant Accounting Policies	3. Significant Accounting Policies (a) Cash and Cash Equivalents The Company considers cash equivalents are highly liquid instruments with a maturity of three months or less at the time of issuance or are readily redeemed into known amounts of cash. As of July 31, 2019, the Company held cash, a term deposit and money market funds. (b) Provisions Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount can be made. If the effect is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. At each financial position reporting date presented the Company has not incurred any provisions. (c) Financial Instruments (i) Classification The Company classifies its financial instruments in the following categories: FVTPL, at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial assets that are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows, and the contractual terms of these financial assets give rise on specified date to cash flows that are solely payments of principal and interest on the principal amount outstanding, are measured at amortized cost Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or the Company has opted to measure them at FVTPL. (ii) Measurement Debt investments at FVTOCI These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognized in other comprehensive income (“OCI”). On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. Equity securities at FVTOCI These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the statements of net loss and comprehensive loss in the period in which they arise. Where management has opted to recognize a financial liability at FVTPL, any changes associated with the Company’s own credit risk will be recognized in other comprehensive income (loss). (iii) Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the statements of comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. (iv) Derecognition Financial assets The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and / or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss. (d) Income Taxes Current income tax Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognized directly in other comprehensive income or equity is recognized in other comprehensive income or equity and not in profit or loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. Deferred income tax Deferred income tax is provided based on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority. (e) Foreign Currency Translation The functional currency of the Company is Canadian dollar, which is the currency of the primary economic environment in which that Company operates. Transactions denominated in foreign currencies are translated using the exchange rate in effect on the transaction date which is approximated by an average rate. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange in effect at the statement of financial position date. Non-monetary items are translated using the historical rate on the date of the transaction. Foreign exchange gains and losses are included in profit or loss. Financial statements of subsidiary companies prepared under their functional currencies are translated into Canadian dollars for consolidation purposes. Amounts are translated using the current rates of exchange for assets and liabilities and using the average rates of exchange for the period for revenues and expenses. Gains and losses resulting from translation adjustments are recorded as other comprehensive income (loss) and accumulated in a separate component of equity, described as foreign currency translation adjustment. In the event of a reduction of the Company’s net investment in its foreign operations, the portion of accumulated other comprehensive income related to the reduction is realized and recognized in operations. (f) Loss Per Share Basic loss per share is computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted loss per share, whereby all “in-the-money” stock options, share purchase warrants and convertible preferred shares are assumed to have been exercised at the beginning of the period and the proceeds from their exercise are assumed to have been used to purchase common shares at the average market price during the period. When a loss is incurred during the period, basic and diluted loss per share are the same as the exercise of stock options, share purchase warrants and convertible preferred shares are considered to be anti-dilutive. (g) Share-based Payments The Company grants share-based awards to employees, directors and non-employees as an element of compensation. The fair value of the awards granted to employees and directors is recognized over the vesting period as share-based compensation expense and share-based payment reserve. The fair value of share-based payments is determined using the Black-Scholes option pricing model using estimates at the date of the grant. At each reporting date prior to vesting, the cumulative expense representing the extent to which the vesting period has expired and management’s best estimate of the awards that are ultimately expected to vest is computed. The movement in cumulative expense is recognized in the statement of comprehensive loss with a corresponding entry within equity, against share-based payment reserve. No expense is recognized for awards that do not ultimately vest. When stock options are exercised, the proceeds received, together with any related amount in share-based payment reserve, are credited to share capital. Share-based payment arrangements with non-employees in which the Company receives goods or services are measured based on the estimated fair value of the goods or services received, unless the fair value cannot be estimated reliably. If the Company cannot reliably estimate the fair value of the goods or services received, the Company will measure their value by reference to the fair value of the equity instruments granted. (h) Share Issuance Costs Professional, consulting, regulatory and other costs directly attributable to financing transactions are recorded as deferred financing costs until the financing transactions are completed, if the completion of the transaction is considered likely; otherwise they are expensed as incurred. Share issue costs are charged to share capital when the related shares are issued. Deferred financing costs related to financing transactions that are not completed are charged to expenses. (i) Share Capital Instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common and convertible preferred shares are classified as equity instruments. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction, net of tax, from the proceeds. The proceeds from issuance of units are allocated between shares and warrants based on the residual method. Under this method, the proceeds are allocated first to share capital based on the fair value of the shares at the time the units are issued and any residual value is allocated to warrant reserve. (j) Adoption of New or Amended Accounting Standards IFRS 9 Financial Instruments: Classification and Measurement - The Company adopted all of the requirements of IFRS 9 for the annual period beginning on August 1, 2019. IFRS 9 replaces IAS 39 Financial Instruments: Recognition and Measurement. IFRS 9 utilizes a revised model for recognition and measurement of financial instruments and a single, forward-looking “expected loss” impairment model. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward in IFRS 9, so the Company’s accounting policy with respect to financial liabilities is unchanged. As a result of the adoption of IFRS 9, management has changed its accounting policy for financial assets retrospectively, for assets that continued to be recognized at the date of initial application. The change did not impact the carrying value of any financial assets or financial liabilities on the transition date. The following table shows the original classification under IAS 39 and the new classification under IFRS 9: Financial assets/liabilities Original classification IAS 39 New classification IFRS 9 Financial assets: Cash and cash equivalents FVTPL FVTPL Financial liabilities: Accounts payable Amortized cost Amortized cost Due to related parties Amortized cost Amortized cost Loans payable Amortized cost Amortized cost IFRS 15 Revenue from Contracts with Customers – IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognized. It has replaced IAS 18 Revenue, IAS 11 Construction Contracts and related interpretations. The new standard establishes a five-step model to account for revenue arising from contracts with customers. Under IFRS 15, revenue is recognized at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The Company has adopted the amendments to IFRS 15 in its financial statements for the annual period beginning on August 1, 2019 with no resulting adjustments. IFRS 2 Share-based Payment In November 2016, the IASB has revised IFRS 2 to incorporate amendments issued by the IASB in June 2016. The amendment provide guidance on the accounting for i) the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments; ii) share-based payment transactions with a net settlement feature for withholding tax obligations and iii) a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. The amendments are effective for annual periods beginning on or after January 1, 2018. Earlier application is permitted. The Company has adopted the amendments to IFRS 2 in its financial statements for the annual period beginning on August 1, 2019 with no resulting adjustments. (k) New Accounting Standards Issued but Not Yet Effective New standards and interpretations not yet adopted Certain new standards, interpretations and amendments to existing standards have been issued by the IASB that are mandatory for future accounting periods with early adoption permitted. Some updates that are not applicable or are not consequential to the Company may have been excluded from the list below. Standard is effective for annual periods beginning on or after January 1, 2019: IFRS 16 Leases - The standard is effective for annual periods beginning on or after January 1, 2019. The Company is assessing the impact of this new standard on its consolidated financial statements.

4. Prepaid Expenses and Deposit

4. Prepaid Expenses and Deposits	12 Months Ended
	Jul. 31, 2019
Notes
4. Prepaid Expenses and Deposits	4. Prepaid Expenses and Deposits July 31, 2019 $ July 31, 2018 $ Insurance 1,432 72,621 Advertising and promotion 71,736 89,894 Consulting 24,797 322,891 Deposits 31,453 46,453 129,418 531,859

5. Convertible Debenture Receiv

5. Convertible Debenture Receivable	12 Months Ended
	Jul. 31, 2019
Notes
5. Convertible Debenture Receivable	5. Convertible Debenture Receivable MichiCann Medical Inc. On February 25, 2019, pursuant to the terms of the Proposed Transaction, the Company advanced $15,000,000 to Michicann pursuant to a senior secured convertible debenture (the “MichiCann Debenture”). The MichiCann Debenture is non-interest bearing, other than in the event of default by MichiCann and matures on October 25, 2019 (the “Maturity Date”). The MichiCann Debenture is secured by way of first ranking security against the personal property of MichiCann. If the Proposed Transaction is not completed by the Maturity Date or MichiCann’s fails to comply with the terms of the MichiCann Debenture and MichiCann pursues an alternative go public transaction or a change of control transaction (an “Alternate Liquidity Transaction”), the Company may elect to convert, in whole or in part, the outstanding amount of the MichiCann Debenture into common shares of MichiCann at a price per MichiCann share that is the lesser if i) $2.50 per MichiCann Share and (ii) a 20% discount to the issue or effective price per Michicann Share under the Alternate Liquidity Transaction. If the Proposed Transaction is not complete by October 25, 2019, MichiCann may elect to prepay the outstanding amount under the MichiCann Debenture, with a prepayment penalty of 10%. The initial fair value of the convertible debenture was determined to be using the Black- Scholes option pricing and discounted cash flow models with following assumptions: estimated share price of ; risk-free interest rate of 1.73%; dividend yield of 0%; stock price volatility of 125% ,an expected life of 0.50 years, As of July 31, 2019, the convertible debenture had an estimated fair value of $15,000,000 using the Black- Scholes option pricing models Subsequent to year end, the Company entered into various amendments to the MichiCann Debenture to extend the Maturity Date to November 30, 2019. Pursuant to the terms of the amendments, if the Proposed Transaction is not complete by January 31, 2020, MichiCann may elect to prepay the outstanding amount under the MichiCann Debenture, with a prepayment penalty of 10%. Harborside Inc. On November 18, 2018 the Company entered into a non-binding memorandum of understanding (“MOU”) with FLRish, Inc., the parent company of Harborside Inc. (“Harborside”). Pursuant to the terms of the MOU with FLRish, Inc., the Company has agreed to provide up to US$10 million in royalty financing to prospective dispensary operators licensing the 'Harborside' brand. Each potential dispensary financing transaction will be assessed by the Company on a case-by-case basis and will be subject to the satisfactory completion of due diligence by the Company and the consummation of definitive documentation with the prospective dispensary operator. In addition, the Company purchased 3,029 units (“Units”) for $3,029,000 of senior unsecured convertible debenture units of FLRish, Inc (“Harborside Debenture”). Each Unit is comprised of: (A) one 12% unsecured convertible debenture, convertible into common shares of Harborside; (i) at the option of the holder at any time prior to the last business day immediately preceding the third anniversary date of the closing; and (ii) automatically upon a Harborside going-public transaction, at a conversion price equal to the lower of (i) $6.90; and (ii) a 10% discount to the price of the common shares of Harborside as part of a qualifying transaction; and (B) 87 common share purchase warrants exercisable for a period of two years following the closing into common shares of Harborside at an exercise price of $8.60 (subject to acceleration in the event of a “going public transaction”). The initial fair value of the convertible debenture was determined to be $2,492,303 using the Black- Scholes option pricing and discounted cash flow models with following assumptions: estimated share price of $5.95 ; conversion price of $6.90 ; risk-free interest rate of 1.91% ; dividend yield of 0% ; stock price volatility of 81% , an expected life of 0.53 years, (See Note 8 (ii) for initial fair value of the warrants). During the year ended July 31, 2019, Harborside completed a reverse-take over (“RTO”) of Lineage Grow Company. On June 10, 2019 Harborside commenced trading on the Canadian Securities Exchange under the symbol “HBOR.” Following the completion of the RTO, the debentures and accrued interest were converted into 567,205 common shares with an estimated fair value of $ 3,573,392. The Company recognized a realized gain on change in fair value of investments in equity investments and convertible debentures of $865,790 for the year ended July 31, 2019.

6. Promissory Note Receivable

6. Promissory Note Receivable	12 Months Ended
	Jul. 31, 2019
Notes
6. Promissory Note Receivable	6. Promissory Note Receivable On August 31, 2018, the Company entered into a definitive agreement, as amended by the Supplemental Agreement dated October 15, 2018 and the Second Supplemental Agreement dated December 26, 2018 (collectively, the “Framework Agreement”), with VLF Holdings LLC, an Oregon limited liability company d/b/a Diem Cannabis (“Diem”) to provide TDMA LLC, a Massachusetts subsidiary of Diem (“TDMA”) with up to US$12.5 million (the “Funding”) over the next three years to develop and operate a large-scale cultivation and processing facility (the “Site”) and up to four dispensaries (the “Dispensaries”). The Funding will be in the form of (i) promissory notes advanced at various stages of development of operations in the state; and (ii) the purchase price for real property acquisitions with respect to Sites and Dispensaries. Newly-formed subsidiaries of RLTY Development MA 1 LLC will acquire title to the real property purchased in respect of the Site and Dispensary acquisitions and will enter into leases (“Leases”) with TDMA (or its nominee) with respect to their operation. The Leases will be “triple net” and will include payments of (i) annual base rent; (ii) percentage rent calculated as 15% of net sales; and (iii) additional rent relating to the costs of property insurance, real estate taxes and any maintenance and repair. The Funding will be secured by (i) guarantees of the payment and performance of all obligations of TDMA by Diem and certain of its subsidiaries (the “Entity Guarantors”) and key individuals (the “Individual Guarantors”); (ii) liens over all of the assets of the Entity Guarantors; and (iii) pledges by the Entity Guarantors and Individual Guarantors of all equity interests in Diem and/or its subsidiaries. Once the Site and Dispensaries are operational and the Leases have been entered into, the Framework Agreement Promissory Note and all subsequently issued promissory notes (including interest accrued thereon) will be deemed satisfied in full. During the year ended July 31, 2019, and pursuant to the Funding, the Company entered into various promissory note agreement s (the “Framework Agreement Promissory Note”) with TDMA for $3,216,274 (US $2,446,208) (July 31, 2018 - $Nil ) as a working capital advance for licenses, Site build out, identification and negotiation of the purchase agreements for the Site and Dispensaries. The Framework Agreement Promissory Note bears interest of 10% per annum and is due on February 28, 2021 , unless earlier satisfied as described below. On August 23, 2019 , the Company entered into a Termination of Framework Agreement (the “Termination”) with Diem. Pursuant to the termination, the Company will convey titles of certain properties (Note 7) to TDMA in exchange of two promissory notes (the “Property Promissory Note”) for US $372,500. The Framework Agreement Promissory Note bears interest of 10% per annum and is due on August 31, 2021 . On September 26, 2019 , the Company entered into a definitive Membership Interest Purchase Agreement (the “MIPA”) with TDMA to acquire all of the issued and outstanding equity in TDMA Orange, LLC, a Diem Cannabis subsidiary. Pursuant to the terms of the MIPA, the Company obtains 100% interest in two cultivation licenses and a processing license in the county of Orange, in the Commonwealth of the State of Massachusetts. As consideration, the Company will forgive the Framework Agreement Promissory Note and Property Promissory Note including accrued interest, cross collateralization and general security arrangement. Continuity for the years ended July 31, 2019 and 2018 is as follows: Total $ Balance, July 31, 2018 and 2017 - Funds advanced 3,216,274 Accrued interest 197,429 Foreign exchange (1,282) Balance, July 31, 2019 3,412,421

7. Land

7. Land	12 Months Ended
	Jul. 31, 2019
Notes
7. Land	7. Land Through the Company’s wholly owned subsidiary and pursuant to the definitive agreement with Diem, RLTY Development Springfield LLC (the “Springfield Property”) and RLTY Development Orange LLC (the “Orange Property”), the Company acquired two Sites. The Company acquired the two Sites for $592,655. Subsequent to July 31, 2019, the Springfield Property and a part of the Orange Property were sold (see Note 6).

8. Investments in Equity Securi

8. Investments in Equity Securities	12 Months Ended
	Jul. 31, 2019
Notes
8. Investments in Equity Securities	8. Investments in Equity Securities Continuity for the years ended July 31, 2019 and 2018 is as follows: Fair value hierarchy level Level 1 Level 3 Level 2 Investments Measured at FVTPL Harborside Inc. Common Shares $ Harborside Inc. Warrants $ Lighthouse Strategies, LLC $ Total $ Balance, July 31, 2018 and 2017 - - - - Addition 3,571,614 536,697 6,574,000 10,682,311 Disposal (2,984,461) - - (2,984,461) Unrealized loss on changes in fair value - (451,970) (4,921,062) ( 5,373,032 Realized loss on changes in fair value (583,898) - - (583,898) Foreign exchange (3,255) (2,666) 31,954 26,033 Balance, July 31, 2019 - 82,061 1,684,892 1,776,953 Harborside Inc. (i) Common shares On May 30, 2019, the Company received 567,205 common shares of Harborside upon the conversion of and as a payment for interest on the Harborside Debenture (Note 5). The shares had an initial fair value of $3,571,614, based on the Harborside RTO offering price. During the year ended July 31, 2019, the Company sold all of its common shares for gross proceeds of $2,984,461 and recorded a foreign exchange loss of $3,255 , and a realized loss on changes in fair value of investments in equity securities of $ (ii) Warrants Pursuant to the terms of the Harborside Debenture (Note 5), the Company received 263,523 share purchase warrants. The initial fair value of the warrants was $536,697 computed using the Black – Scholes option pricing model based on the following assumptions: estimated share price of $5.95; exercise price of $8.60; risk-free interest rate of 2.20%; dividend yield of 0%; stock price volatility of 81% and an expected life of 2 years. As at July 31, 2019, the warrants remain unexercised with a fair value of $82,061 computed using the Black – Scholes option pricing model based on the following assumptions: estimated share price of $3.10; exercise price of $8.60; risk-free interest rate of 1.61%; dividend yield of 0%; stock price volatility of 81% and an expected life of 1.3 years. The Company recognized an unrealized loss on investments in equity securities of $451,970 for the year ended July 31, 2019. Lighthouse Strategies, LLC On January 9, 2019 the Company closed its strategic investment of $6,574,000 (US $5,000,000) in Lighthouse Strategies LLC (“Lighthouse”) Series A membership units concurrently with a financing arrangement for certain Lighthouse beverage lines. Pursuant to the Financing Fee Agreement, the Company is entitled to 1% of net sales of certain of Lighthouse’s beverage lines, including Cannabiniers, Two Roots Brewing Co and Creative Waters Beverage Company (“Financing Fees”). Financing Fees will accrue until December 1, 2019, at which point the Company may choose to receive such fees in cash or Series A membership units of Lighthouse. Thereafter, financing fees are payable quarterly in cash. The terms of the Financing Fee Agreement are between four and six years, depending on certain milestones and includes acceleration provisions in certain events (including a substantial asset divestiture, change of control, or initial public offering). Management estimated that the 1% royalty of net sales had a fair value of $Nil and the entire transaction price was allocated to the membership units. As at July 31, 2019, the investment had an estimated fair value of $1,684,892 based on Lighthouse’s most recent financing preceding July 31, 2019. The Company recognized an unrealized loss on investments in equity securities of $4,921,062 for the year ended July 31, 2019.

9. Accounts Payable and Accrued

9. Accounts Payable and Accrued Liabilities	12 Months Ended
	Jul. 31, 2019
Notes
9. Accounts Payable and Accrued Liabilities	9. Accounts Payable and Accrued Liabilities July 31, 2019 $ July 31, 2018 $ Accounts payables 304,540 235,357 Accrued liabilities 32,000 76,000 336,540 311,357

10. Related Party Transactions

10. Related Party Transactions and Balances	12 Months Ended
	Jul. 31, 2019
Notes
10. Related Party Transactions and Balances	10. Related Party Transactions and Balances The Company has identified its directors and certain senior officers as its key management personnel. K ey management compensation for the years ended July 31, 2019 and 2018 is as follows: 2019 $ 2018 $ Short-term employee benefits: Consulting fees 195,164 463,602 Salary and benefits 476,763 180,420 671,927 644,022 Share-based compensation 1,403,282 1,651,395 Total 2,075,209 2,295,417 During the year, the Company paid $4,000 in rent (2018 - $9,100 ) to related parties comprised of directors, officers and companies with common directors. As at July 31, 2019, the amount due to related parties was $21,347 (2018 - $18,685 ). The amounts are unsecured, non-interest bearing and due on demand.

11. Share Capital

11. Share Capital	12 Months Ended
	Jul. 31, 2019
Notes
11. Share Capital	11. Share Capital Authorized Unlimited number of common shares without par value, and unlimited number of Series 1 Convertible Preferred shares without par value, participating, each share convertible into one common share by the holder, and non-voting. Issued and Outstanding As at July 31, 2019, there were 50,900,000 (2018 - 40,000,000 ) Series 1 Convertible Preferred Shares and 292,607,662 (2018 - 227,787,662 ) common shares issued and outstanding. Convertible Preferred Shares During the year ended July 31, 2019: During the year ended July 31, 2019, the Company issued 40,000,000 Series 1 Convertible Preferred shares pursuant to the exercise of 40,000,000 of Preferred Share warrants. The Company received the proceeds during the year ended July 31, 2018. The Company reclassified $2,000,000 from convertible preferred shares issuable to convertible preferred shares. During the year ended July 31, 2019, 29,100,000 convertible preferred shares were converted into common shares. The Company reclassified $1,365,780 from convertible preferred shares to common shares. During the year ended July 31, 2018: On May 25, 2018 , the Company issued 40,000,000 units in the capital of the Company at a price of $0.05 per unit for gross proceeds of $2,000,000 . Each unit consists of one Series 1 Convertible Preferred share (a “Preferred Share”) and one preferred share purchase warrant; each warrant (a “Warrant”) is exercisable by the holder to acquire one additional Preferred Share in the capital of the Company at a price of $0.05 for a period of 24 months following the issuance date. Common Shares During the year ended July 31, 2019: During the year ended July 31, 2019, the Company issued 17,810,000 common shares pursuant to the exercise of 17,810,000 warrants for gross proceeds of $890,500 . On September 26, 2018 , 4,000,000 special finder’s warrants issued on May 25, 2018 with a carrying value of $141,440 were converted into an equivalent number of units in the capital of the Company . Each unit consists of one common share and one common share purchase warrant; each warrant entitling the holder to acquire one additional share at $0.05 for a period of 24 months. Upon conversion, the carrying value of $141,440 was allocated to common shares and $nil to the warrants based on the residual method. On August 31, 2018 , 1 2,690,000 special warrants and 1,220,000 special finders’ warrants issued on April 26, 2018 with a carrying value of $ 695,500 were converted into an equivalent number of units in the capital of the Company . Each unit consists of one common share and one common share purchase warrant; each warrant entitling the holder to acquire one additional share at $0.05 expiring on April 26, 2020. Upon conversion, the carrying value of $695,500 was allocated to common shares and $nil to the warrants based on the residual method. For the year ended July 31, 2018: On June 8, 2018 , the Company converted 59,370,000 special warrants and 3,757,000 special finders’ warrants issued on February 8, 2018 into an equivalent number of units in the capital of the Company . Each unit consists of one common share and one common share purchase warrant; each warrant entitling the holder to acquire one additional share at $0.05 for a period of 24 months. Upon conversion, the carrying value of $3,156,350 was allocated to common shares and $nil to the warrants based on the residual method. On June 12, 2018 , the Company issued 94,355,026 common shares at a price of $0.33 per common share for gross proceeds of $31,137,159 . In consideration for their services, the underwriters received a cash commission of $2,067,500 and the Company paid other legal and finder’s fees of $64,000 . A total of 5,182,365 finder’s warrants were granted with a fair value of $1,209,136 ; each finder warrant entitling the holder to acquire one additional common share at $0.33 for a period of 24 months. The fair value of the finders’ warrants was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price - $0.33 ; exercise price - $0.33 ; expected life – 2 years; volatility – 147% ; dividend yield – $0 ; and risk-free rate – 1.90% . During the period ended July 31, 2018, the Company issued 5,050,000 common shares pursuant to the exercise of 5,050,000 warrants for gross proceeds of $252,500 . On July 1, 2018 , the Company converted 57,120,000 special warrants and 5,292,000 special finders’ warrants issued on March 1, 2018 into an equivalent number of units in the capital of the Company . Each unit consists of one common share and one share purchase warrant; each warrant entitling the holder to acquire one additional share at $0.05 for a period of 24 months. Upon conversion, the carrying value of $2,856,000 was allocated to common shares and $nil to the warrants based on the residual method. Stock Options Under the Company’s stock option plan (the “Plan”) the Company has adopted a 20% rolling stock option plan (“Plan”) to replace its previous 10% rolling plan. The Plan provides that the Board may from time to time, in its discretion, grant to directors, officers, employees, technical consultants and other participants to the Company, non-transferrable stock options to purchase common shares, provided that the number of common shares reserved for issuance will not exceed 20% of the Company’s issued and outstanding common shares. Such options will be exercisable for a period of up to ten years from the date of grant. In addition, the number of common shares which may be issuable under the Plan within a one year period: (i) to any one individual shall not exceed 5% of the issued and outstanding common shares; and (ii) to a consultant or an employee performing investor relations activities, shall not exceed 2% of the issued and outstanding common shares. The underlying purpose of the Plan is to attract and motivate the directors, officers, employees and consultants of the Company and to advance the interests of the Company by affording such persons with the opportunity to acquire an equity interest in the Company through rights granted under the Plan. During the year ended July 31, 2019: On August 16, 2018 , the Company granted 1,000,000 stock options to an employee of the Company with an exercise price of $0.73 (US $ 0.56) with a term of 5 years. The options vest 12.5% every 3 months. The estimated fair value of the stock options was measured using the Black-Scholes Option Pricing Model with the following assumptions: stock price - $0.74 (US $ 0.50); exercise price - $0.73 (US $ 0.56); expected life – 5 years, volatility – 147% , dividend yield - $0 ; and risk-free rate – 2.18% . During the year ended July 31, 2019, the Company recognized $145,052 in share-based compensation expense related to these stock options. During the year ended July 31, 2019, 1,000,000 of these stock options were forfeited. On September 24, 2018 , the Company granted 100,000 stock options to a consultant of the Company with an exercise price of $0.31 (US $ 0.24) with a term of 2 years. The options vest 12.5% every 3 months. The estimated fair value of the stock options was measured using the Black-Scholes Option Pricing Model with the following assumptions: stock price - $0.31 (US $ 0.24); exercise price - $0.31 (US $ 0.24); expected life – 2 years, volatility – 147% , dividend yield - $0 ; and risk-free rate – 2.13% . During year ended July 31, 2019, the Company recognized $12,274 in share-based compensation expense related to these stock options. On December 12, 2018 , the Company granted 5,750,000 stock options to consultants of the Company with an exercise price of $0.15 (US$ 0.12) with a term of 5 years. The options vest 12.5% every 3 months. The estimated fair value of the stock options was measured using the Black-Scholes Option Pricing Model with the following assumptions: stock price - $0.15 (US$ 0.12); exercise price - $0.15 (US$ 0.12); expected life – 5 years, volatility – 147% , dividend yield - $0 ; and risk-free rate – 2.07% . During year ended July 31, 2019, the Company recognized $151,349 in share-based compensation expense related to these stock options. During the period ended July 31, 2019, 5,030,000 of these stock options were forfeited. During the year ended July 31, 2019, the Company granted 20,327,039 stock options to directors, officers and consultants of the Company with an exercise price of $0.34 (US$ 0.26) with a term of 5 years and vested immediately. The estimated fair value of the stock options was measured using the Black-Scholes Option Pricing Model with the following assumptions: stock price - $0.34 (US$ 0.26); exercise price - $0.34 (US$ 0.26); expected life – 5 years, volatility – 147% , dividend yield - $0 ; and risk-free rate – 1.52% . During year ended July 31, 2019, the Company recognized $6,426,936 in share-based compensation expense related to these stock options. During the year ended July 31, 2018: On June 22, 2018 , the Company granted 16,468,727 stock options to various directors, officers and consultants of the Company with an exercise price of $0.33 with a term of 5 years. 9,981,227 of the stock options vested immediately, with the remainder vesting 12.5% every 3 months. The estimated fair value of the stock options was measured using the Black-Scholes Option Pricing Model with the following assumptions: stock price - $0.33 ; exercise price - $0.33 ; expected life – 5 years, volatility – 147% , dividend yield - $0 ; and risk-free rate – 1.98% . During the year ended July 31, 2018, the Company recognized $3,250,476 in share-based compensation expense related to these stock options. During year period ended July 31, 2019, the Company recognized $594,189 in share-based compensation expense related to these stock options. During the period ended July 31, 2019, 8,980,000 of these stock options were forfeited. Continuity of stock options outstanding during the year ended July 31, 2019 and 2019 are as follows: Options outstanding Weighted average exercise price $ Balance, July 31, 2017 - - Issued 16,468,727 0.33 Balance, July 31, 2018 16,468,727 0.33 Forfeited (15,010,000) (0.30) Issued 27,177,039 0.31 Balance, July 31, 2019 28,635,766 0.33 As at July 31, 2019, the outstanding and exercisable stock options are as follows: Expiry Date Exercise price $ Number of options # Exercisable options # September 24, 2020 US $0.24 100,000 37,500 April 26, 2024 US $0.26 20,327,039 20,327,039 June 22, 2023 0.33 7,488,727 6,426,227 December 12, 2023 US $0.12 720,000 180,000 0.33 28,635,766 26,970,766 Special Warrants On February 8, 2018 , the Company completed a non-brokered private placement, of 59,370,000 special warrants of the Company at a price of $0.05 per special warrant for gross proceeds of $2,968,500 . Each special warrant entitled the holder to receive, without payment of any additional consideration or need for further action, one unit of the Company, each unit comprising of one common share and one share purchase warrant; each warrant entitling the holder to acquire one additional share at $0.05 for a period of 24 months. An additional 3,757,000 special warrants were issued as finders’ fees with the same terms as the special warrants pursuant to the private placement. The estimated fair value of $187,850 was charged to warrant issue costs. On June 8, 2018 , the Company converted the special warrants and special finders’ warrants into an equivalent number of units in the capital of the Company . On March 1, 2018 , the Company completed a non-brokered private placement, of 57,120,000 special warrants of the Company at a price of $0.05 per special warrant for gross proceeds of $2,856,000 . Each special warrant entitled the holder to receive, without payment of any additional consideration or need for further action, one unit of the Company, each unit comprising of one common share and one share purchase warrant; each warrant entitling the holder to acquire one additional share at $0.05 for a period of 24 months. An additional 5,292,000 special warrants were issued as finders’ fees with the same terms as the special warrants pursuant to the private placement. The estimated fair value of the finder’s warrants $264,600 was charged to warrant issue costs. On July 1, 2018 , the Company converted the special warrants and special finders’ warrants into an equivalent number of units in the capital of the Company . On April 30, 2018 , the Company completed a non-brokered private placement, of 12,690,000 special warrants of the Company at a price of $0.05 per special warrant for gross proceeds of $634,500 . Each special warrant entitled the holder to receive, without payment of any additional consideration or need for further action, one unit of the Company, each unit comprising of one common share and one share purchase warrant; each warrant entitling the holder to acquire one additional share at $0.05 for a period of 24 months. An additional 1,220,000 special warrants were issued as finders’ fees with the same terms as the special warrants received pursuant to the private placement. The estimated fair value of the finder’s warrants $61,000 was charged to warrant issue costs. As at July 31, 2018, 13,910,000 special warrants and special finders’ warrants were outstanding and a total of $695,500 has been classified in warrant reserve in relation to these special warrants and special finders’ warrants. On August 31, 2018 , the Company converted the special warrants and special finders’ warrants into an equivalent number of units in the capital of the Company . On May 25, 2018 , the Company granted 4,000,000 special finders’ warrants as finder’s fees to the May 25, 2018 issuance with a fair value of $141,440 . The fair value of the special finders’ warrants was determined using the Black Scholes Option Pricing Model with the following assumptions: stock price - $0.05 ; exercise price - $0.05 ; expected life – 2 years; volatility – 147% ; dividend yield – $0 ; and risk-free rate – 1.96% . Each special finders warrant entitled the holder to receive, without payment of any additional consideration or need for further action, one unit of the Company, each unit comprising of one common share and one common share purchase warrant on September 26, 2018. Each share purchase warrant is exercisable by the holder to acquire one additional common share in the capital of the Company at a price of $0.05 for a period of 24 months following the issuance date of the convertible preferred share units. Accordingly these special finder’s warrants are presented as an addition to warrant reserves on the Statement of Equity. As at July 31, 2018, 4,000,000 special finder’s warrants were outstanding and a total of $ 141,440 has been classified in warrant reserve in relation to these special warrants. On September 26, 2018 , the Company converted the special finders’ warrants into an equivalent number of units in the capital of the Company . Common Share Purchase Warrants The continuity of the Company's common share purchase warrants pursuant to the special warrants is as follows: Number of share purchase warrants # Weighted average exercise price $ Outstanding, July 31, 2017 - - Issued 130,721,365 0.06 Exercised (5,050,000) 0.05 Outstanding, July 31, 2018 125,671,365 0.06 Issued 17,910,000 0.05 Exercised (17,810,000) 0.05 Outstanding, July 31, 2019 125,771,365 0.06 As of July 31, 2019, the Company had share purchase warrants outstanding and exercisable to acquire common shares of the Company as follows: Expiry Date Exercise price $ Number of warrants # February 8, 2020 0.05 57,607,000 March 1, 2020 0.05 47,512,000 April 30, 2020 0.05 15,470,000 June 11, 2020 0.33 5,182,365 125,771,365

12. Financial Instruments and R

12. Financial Instruments and Risks	12 Months Ended
	Jul. 31, 2019
Notes
12. Financial Instruments and Risks	12. Financial Instruments and Risks (a) Fair Values and Classification The Company’s financial instruments consist of cash and cash equivalent, convertible debenture receivable, promissory note receivable, long-investments, accounts payable, due to related parties and loan payable. Financial instruments are classified into one of the following categories: FVTPL, FVTOC, or amortized cost. The carrying values of the Company’s financial instruments are classified into the following categories: Financial Instrument Category July 31 , 2019 July 31 , 2018 Cash and cash equivalents FVTPL $ 2,961,514 $ 33,904,759 Convertible debenture receivable FVTPL 15,000,000 - Promissory note receivable FVTPL 3,412,421 - Investments in equity securities FVTPL 1,766,953 - Accounts payable Amortized cost 304,540 235,357 Due to related parties Amortized cost 21,347 18,685 Loans payable Amortized cost - 10,000 The Company applied the following fair value hierarchy which prioritizes the inputs used in the valuation methodologies in measuring fair value into three levels. The three levels are defined as follows: a) Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities; b) Level 2 – Inputs other than quoted prices that are observable for assets or liabilities, either directly or indirectly; and c) Assets and liabilities are classified in entirety based on the lowest level of input that is significant to the fair measurement. The Company’s financial assets measured on a recurring basis at fair value are as follows: July 31, 2019 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 2,961,514 $ - $ - $ 2,961,514 Convertible debenture receivable - - 15,000,000 15,000,000 Promissory note receivable - 3,412,421 - 3,412,421 Investments in membership units - 1,684,892 - 1,684,892 Investments in warrants - - 82,061 82,061 July 31, 2018 Level 1 Level 2 Level 3 Total Cash $ 33,904,759 $ - $ - $ 33,904,759 Changes in level 3 items are as follows: Convertible debenture receivable Investments in warrants Balance, July 31, 2018 and 2017 $ - $ - Additions 17,492,303 536,697 Conversion of debenture (3,365,556) - Unrealized loss on changes in fair value - (451,970) Realized gain on changes in fair value 865,790 Foreign exchange 7,463 (2,666) Balance, July 31, 2019 $ 15,000,000 $ 82,061 The fair value of accounts payables, due to related parties and loan payable approximates their carrying value due to their short-term maturity. (b) Credit Risk Credit risk is the risk that one party to a financial instrument will fail to discharge an obligation and cause the other party to incur a financial loss. The Company’s maximum credit risk is equal to the carrying value of cash and cash equivalents, deposits, convertible debenture receivable and promissory note receivable. The Company deposits the majority of its cash with high credit quality financial institutions in Canada. Therefore, management considers its exposure to credit risk arising from its cash to be minimal. (c) Foreign Exchange Rate and Interest Rate Risk Foreign exchange rate Foreign currency risk is limited to the portion of the Company’s business transactions denominated in currencies other than the Canadian dollar. The Company has not entered into any foreign currency contracts to mitigate this risk, but manages the risk by minimizing the value of financial instruments denominated in foreign currency. The Company is exposed to foreign currency risk to the extent that the following monetary assets and liabilities are denominated in US dollars: July 31, 2019 July 31, 2018 Balance in US dollars: Cash and cash equivalents $ - $ 15,126,020 Prepaid expenses and deposits 250,000 Promissory note receivable 2,595,392 - Accounts payable - (46,138) Net exposure 2,845,392 $ 15,079,882 Balance in Canadian dollars: $ 3,741,121 $ 19,629,482 A 10% change in the US dollar to the Canadian dollar exchange rate would impact the Company’s net loss by approximately $374,000 for the year ended July 31, 2019 (July 31,2017 - $1,960,000). Interest rate risk Interest rate risk consists of two components: i) To the extent that payments made or received on the Company’s monetary assets and liabilities are affected by changes in the prevailing market interest rates, the Company is exposed to interest rate cash flow risk. ii) To the extent that changes in prevailing market rates differ from the interest rate in the Company’s monetary assets and liabilities, the Company is exposed to interest rate price risk. The Company is exposed to interest rate risk with respect to its convertible debenture receivable (see Note 5) and its promissory note receivable (see Note 6). (c) Liquidity Risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company currently settles its financial obligations using cash. The ability to do so relies on the Company raising equity financing in a timely manner. The Company manages liquidity risk through the management of its capital structure and financial leverage as outlined in Note 14. The following are contractual maturities of financial liabilities as at July 31, 2019: Carrying amount Contractual cash flows Within 1 year Accounts payable and accrued liabilities $ 336,540 $ 336,540 $ 336,540 Due to related parties 21,347 21,347 21,347 The following are contractual maturities of financial liabilities as at July 31, 2018: Carrying amount Contractual cash flows Within 1 year Accounts payable and accrued liabilities $ 311,357 $ 311,357 $ 311,357 Due to related parties 18,685 18,685 18,685 Loans payable 10,000 10,000 10,000

13. Income Taxes

13. Income Taxes	12 Months Ended
	Jul. 31, 2019
Notes
13. Income Taxes	13. Income Taxes The tax effect (computed by applying the Canadian federal and provincial statutory rate) of the significant temporary differences, which comprise deferred tax assets and liabilities, are as follows : 2019 $ 2018 $ Net loss before income taxes (18,611,721) (7,825,089) Canadian statutory income tax rate 27.00% 26.50% Expected income tax recovery at statutory rate 5,025,165 2,073,649 Tax effect of: Other non-deductible expense 2,095,667 (96,209) Difference between income tax rates (303,226) - Change in tax rate - 20,314 Change in unrecognized deferred tax assets (6,817,606) (1,997,754) Income tax recovery - - The significant components of deferred income tax assets and liabilities are as follows: 2019 $ 2018 $ Deferred income tax assets: Non-capital losses carried forward 7,583,620 1,753,878 Resource pools 694,023 681,172 Investment in equity securities 1,121,010 - Share issuance costs 473,032 619,029 Total gross deferred income tax assets 9,871,685 3,054,079 Unrecognized deferred tax assets (9,871,685) (3,054,079) Net deferred income tax assets - - As at July 31, 2018, the Company has non-capital losses carried forward of approximately $28,088,000 which are available to offset future years’ taxable income. These losses expire as follows: $ 2030 300 2031 96,900 2032 139,400 2033 225,600 2034 18,300 2035 122,000 2036 60,000 2037 32,500 2038 5,125,000 2039 22,268,000 28,088,000 The Company also has certain allowances in respect of resource development and exploration costs of approximately $2,570,000 (2018 - $2,570,000) which, subject to certain restrictions, are available to offset against future taxable income. The application of non-capital losses and resource development and exploration costs against future taxable income is subject to final determination of the respective amounts by the Canada Revenue Agency.

14. Capital Management

14. Capital Management	12 Months Ended
	Jul. 31, 2019
Notes
14. Capital Management	14. Capital Management The Company’s objectives when managing capital are to identify and pursue business opportunities, to maintain financial strength, to protect its ability to meet its on-going liabilities, to continue as a going concern, to maintain creditworthiness and to maximize returns for shareholders over the long term. The Company does not have any externally imposed capital requirements to which it is subject. The Company's principal source of funds is through the issuance of equity. Management considers all components of shareholders' equity as capital. The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares while minimizing dilution for its existing shareholders. The Company’s overall strategy with respect to capital risk management remains unchanged from the year ended July 31, 2019.

15. Segment Information

15. Segment Information	12 Months Ended
	Jul. 31, 2019
Notes
15. Segment Information	15. Segment Information The Company currently operates in a single reportable operating segment. For the year ended July 31, 2019, the Company operated in two geographical areas being Canada and the United States of America. Canada United States of America Total Non-current assets other than financial instruments $ - $ 592,655 $ 592,655 For the year ended July 31, 2018, non-current assets other tan financial instruments were located in Canada.

16. Commitments

16. Commitments	12 Months Ended
	Jul. 31, 2019
Notes
16. Commitments	16. Commitments Office Premises During the year ended July 31, 2019, the Company entered into an office lease. The lease expires on September 2, 2020 and has the following estimated annual payments: $ 2020 294,205 2021 49,034 343,239 Definitive Agreement The Definitive Agreements contemplates the following terms: - The Company will complete a share consolidation on an 8:1 basis; - Change its name to “Red White & Bloom Inc.” or such other name as may be approved by the board of directors; - As at November 28, 2019, the transaction had not yet closed.

17. Subsequent Events

17. Subsequent Events	12 Months Ended
	Jul. 31, 2019
Notes
17. Subsequent Events	17. Subsequent Events a) Subsequent to year end, the Company issued 9,165,000 common shares pursuant to warrant exercises for gross proceeds of $458,250 . b) Subsequent to year end, the Company entered into a definitive Membership Interest Purchase Agreement and obtained 100% interest in two covenant cultivation licenses and a processing license (Collectively, “Licenses”) in the county of Orange, in the Commonwealth of the state of Massachusetts in lieu of the forgiveness of the Framework Agreement Promissory Note (Note 6).

2. Basis of Preparation and S_2

2. Basis of Preparation and Statement of Compliance: Statement of Compliance (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Statement of Compliance	Statement of Compliance These consolidated financial statements have been prepared in accordance International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board. The consolidated financial statements were approved and authorized for issuance by the Board of Directors on November 28, 2019.

2. Basis of Preparation and S_3

2. Basis of Preparation and Statement of Compliance: Basis of Presentation (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Basis of Presentation	Basis of Presentation The consolidated financial statements have been prepared on a historical cost basis except for financial instruments described in Note 3(c), which are measured at fair value.

2. Basis of Preparation and S_4

2. Basis of Preparation and Statement of Compliance: Functional and Presentation Currency (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Functional and Presentation Currency	Functional and Presentation Currency These financial statements are presented in Canadian dollars. The functional currency of each entity is determined using the currency of the primary economic environment in which the entity operates. The Company’s functional currency, as determined by management, is the Canadian dollar. The Company’s US subsidiaries functional currencies, as determined by management, are the United States dollar.

2. Basis of Preparation and S_5

2. Basis of Preparation and Statement of Compliance: Basis of Consolidation (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Basis of Consolidation	Basis of Consolidation During the year ended July 31, 2019, the Company incorporated several subsidiaries. As at July 31, 2019, the Company’s structure includes Tidal Royalty Corp., the parent company incorporated pursuant to the laws of the Business Corporations Act (British Columbia), and the following subsidiaries: Entity Domicile of Incorporation % of interest at July 31, 2019 Royalty USA Corp. Delaware , USA 100% RLTY Beverage 1 LLC Delaware , USA 100% RLTY Development MA 1 LLC Delaware , USA 100% RLTY Development 1 NV 1 LLC Delaware , USA 100% RLTY Development Orange LLC Massachusetts , USA 100% RLTY Development Springfield LLC Massachusetts , USA 100% RLTY Service LLC Delaware , USA 100% RLTY Development FLA 1 LLC Delaware , USA 100% RLTY Development FLA 2 LLC Delaware , USA 100% RLTY Development CA 1 LLC Delaware , USA 100% These consolidated financial statements include the accounts of the Company and its controlled entities. Control is achieved when the Company has the power to govern the financial operating policies of an entity so as to obtain benefits from its activities. Subsidiaries are fully consolidated from the date on which control is transferred to the Company until the date on which control ceases. All inter-company transactions, balances, income and expenses are eliminated in full upon consolidation.

2. Basis of Preparation and S_6

2. Basis of Preparation and Statement of Compliance: Use of Estimates and Judgments (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Use of Estimates and Judgments	Use of Estimates and Judgments The preparation of financial statements in accordance with IFRS requires management to make estimates and assumptions about the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities, and the results of operations. Significant assumptions about the future and other sources of estimation uncertainty that management has made at the statement of financial position date, that could result in a material adjustment to the carrying amounts of assets and liabilities, in the event that actual results differ from assumptions made, relate to, but are not limited to, the following: Significant accounting estimates: i) Investments in equity securities, convertible and promissory notes receivable Management uses valuation techniques in measuring the fair value of investments in equity securities, convertible and promissory notes receivable. In applying the valuation techniques management makes maximum use of market inputs wherever possible, and uses estimates and assumptions that are, as far as possible, consistent with observable data that market participants would use in pricing the instrument. Where applicable data is not observable, company-specific information is considered when determining whether the fair value of a investment in equity securities or convertible and promissory notes receivable should be adjusted upward or downward at the end of each reporting period. In addition to company-specific information, the Company will take into account trends in general market conditions and the share performance of comparable publicly-traded companies when valuing investment in equity securities, convertible and promissory notes receivable. ii) Share-based payment transactions Management uses the Black-Scholes pricing model to determine the fair value of stock options and standalone share purchase warrants issued. This model requires assumptions of the expected future price volatility of the Company’s common shares, expected life of options and warrants, future risk-free interest rates and the dividend yield of the Company’s common shares. Significant accounting judgements: i) Going concern The assessment of the Company’s ability to continue as a going concern involves management judgement about the Company’s resources and future prospects. ii) Income taxes Management exercises judgment to determine the extent to which deferred tax assets are recoverable, and can therefore be recognized in the statements of financial position and comprehensive income or loss.

3. Significant Accounting Pol_2

3. Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Cash and Cash Equivalents	(a) Cash and Cash Equivalents The Company considers cash equivalents are highly liquid instruments with a maturity of three months or less at the time of issuance or are readily redeemed into known amounts of cash. As of July 31, 2019, the Company held cash, a term deposit and money market funds.

3. Significant Accounting Pol_3

3. Significant Accounting Policies: Provisions (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Provisions	(b) Provisions Provisions are recorded when a present legal or constructive obligation exists as a result of past events where it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate of the amount can be made. If the effect is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and, where appropriate, the risks specific to the liability. At each financial position reporting date presented the Company has not incurred any provisions.

3. Significant Accounting Pol_4

3. Significant Accounting Policies: Financial Instruments (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Financial Instruments	(c) Financial Instruments (i) Classification The Company classifies its financial instruments in the following categories: FVTPL, at fair value through other comprehensive income (loss) (“FVTOCI”) or at amortized cost. The Company determines the classification of financial assets at initial recognition. The classification of debt instruments is driven by the Company’s business model for managing the financial assets and their contractual cash flow characteristics. Equity instruments that are held for trading are classified as FVTPL. For other equity instruments, on the day of acquisition the Company can make an irrevocable election (on an instrument-by-instrument basis) to designate them as at FVTOCI. Financial assets that are held within a business model whose objective is to hold financial assets in order to collect contractual cash flows, and the contractual terms of these financial assets give rise on specified date to cash flows that are solely payments of principal and interest on the principal amount outstanding, are measured at amortized cost Financial liabilities are measured at amortized cost, unless they are required to be measured at FVTPL (such as instruments held for trading or derivatives) or the Company has opted to measure them at FVTPL. (ii) Measurement Debt investments at FVTOCI These assets are subsequently measured at fair value. Interest income calculated using the effective interest method, foreign exchange gains and losses and impairment are recognised in profit or loss. Other net gains and losses are recognized in other comprehensive income (“OCI”). On derecognition, gains and losses accumulated in OCI are reclassified to profit or loss. Equity securities at FVTOCI These assets are subsequently measured at fair value. Dividends are recognised as income in profit or loss unless the dividend clearly represents a recovery of part of the cost of the investment. Other net gains and losses are recognized in OCI and are never reclassified to profit or loss. Financial assets and liabilities at amortized cost Financial assets and liabilities at amortized cost are initially recognized at fair value plus or minus transaction costs, respectively, and subsequently carried at amortized cost less any impairment. Financial assets and liabilities at FVTPL Financial assets and liabilities carried at FVTPL are initially recorded at fair value and transaction costs are expensed in the statements of loss and comprehensive loss. Realized and unrealized gains and losses arising from changes in the fair value of the financial assets and liabilities held at FVTPL are included in the statements of net loss and comprehensive loss in the period in which they arise. Where management has opted to recognize a financial liability at FVTPL, any changes associated with the Company’s own credit risk will be recognized in other comprehensive income (loss). (iii) Impairment of financial assets at amortized cost The Company recognizes a loss allowance for expected credit losses on financial assets that are measured at amortized cost. At each reporting date, the Company measures the loss allowance for the financial asset at an amount equal to the lifetime expected credit losses if the credit risk on the financial asset has increased significantly since initial recognition. If at the reporting date, the financial asset has not increased significantly since initial recognition, the Company measures the loss allowance for the financial asset at an amount equal to the twelve month expected credit losses. The Company shall recognize in the statements of comprehensive loss, as an impairment gain or loss, the amount of expected credit losses (or reversal) that is required to adjust the loss allowance at the reporting date to the amount that is required to be recognized. (iv) Derecognition Financial assets The Company derecognizes financial assets only when the contractual rights to cash flows from the financial assets expire, or when it transfers the financial assets and substantially all of the associated risks and rewards of ownership to another entity. Financial liabilities The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expire. The Company also derecognizes a financial liability when the terms of the liability are modified such that the terms and / or cash flows of the modified instrument are substantially different, in which case a new financial liability based on the modified terms is recognized at fair value. Gains and losses on derecognition are generally recognized in profit or loss.

3. Significant Accounting Pol_5

3. Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Income Taxes	(d) Income Taxes Current income tax Current income tax assets and liabilities for the current period are measured at the amount expected to be recovered from or paid to the taxation authorities. The tax rates and tax laws used to compute the amount are those that are enacted or substantively enacted, at the reporting date. Current income tax relating to items recognized directly in other comprehensive income or equity is recognized in other comprehensive income or equity and not in profit or loss. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate. Deferred income tax Deferred income tax is provided based on temporary differences at the reporting date between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes. The carrying amount of deferred income tax assets is reviewed at the end of each reporting period and recognized only to the extent that it is probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized. Deferred income tax assets and liabilities are measured at the tax rates that are expected to apply to the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred income tax assets and deferred income tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current income tax liabilities and the deferred income taxes relate to the same taxable entity and the same taxation authority.

3. Significant Accounting Pol_6

3. Significant Accounting Policies: Foreign Currency Translation (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Foreign Currency Translation	(e) Foreign Currency Translation The functional currency of the Company is Canadian dollar, which is the currency of the primary economic environment in which that Company operates. Transactions denominated in foreign currencies are translated using the exchange rate in effect on the transaction date which is approximated by an average rate. Monetary assets and liabilities denominated in foreign currencies are translated at the rate of exchange in effect at the statement of financial position date. Non-monetary items are translated using the historical rate on the date of the transaction. Foreign exchange gains and losses are included in profit or loss. Financial statements of subsidiary companies prepared under their functional currencies are translated into Canadian dollars for consolidation purposes. Amounts are translated using the current rates of exchange for assets and liabilities and using the average rates of exchange for the period for revenues and expenses. Gains and losses resulting from translation adjustments are recorded as other comprehensive income (loss) and accumulated in a separate component of equity, described as foreign currency translation adjustment. In the event of a reduction of the Company’s net investment in its foreign operations, the portion of accumulated other comprehensive income related to the reduction is realized and recognized in operations.

3. Significant Accounting Pol_7

3. Significant Accounting Policies: Loss Per Share (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Loss Per Share	(f) Loss Per Share Basic loss per share is computed using the weighted average number of common shares outstanding during the period. The treasury stock method is used for the calculation of diluted loss per share, whereby all “in-the-money” stock options, share purchase warrants and convertible preferred shares are assumed to have been exercised at the beginning of the period and the proceeds from their exercise are assumed to have been used to purchase common shares at the average market price during the period. When a loss is incurred during the period, basic and diluted loss per share are the same as the exercise of stock options, share purchase warrants and convertible preferred shares are considered to be anti-dilutive.

3. Significant Accounting Pol_8

3. Significant Accounting Policies: Share-based Payments (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Share-based Payments	(g) Share-based Payments The Company grants share-based awards to employees, directors and non-employees as an element of compensation. The fair value of the awards granted to employees and directors is recognized over the vesting period as share-based compensation expense and share-based payment reserve. The fair value of share-based payments is determined using the Black-Scholes option pricing model using estimates at the date of the grant. At each reporting date prior to vesting, the cumulative expense representing the extent to which the vesting period has expired and management’s best estimate of the awards that are ultimately expected to vest is computed. The movement in cumulative expense is recognized in the statement of comprehensive loss with a corresponding entry within equity, against share-based payment reserve. No expense is recognized for awards that do not ultimately vest. When stock options are exercised, the proceeds received, together with any related amount in share-based payment reserve, are credited to share capital. Share-based payment arrangements with non-employees in which the Company receives goods or services are measured based on the estimated fair value of the goods or services received, unless the fair value cannot be estimated reliably. If the Company cannot reliably estimate the fair value of the goods or services received, the Company will measure their value by reference to the fair value of the equity instruments granted.

3. Significant Accounting Pol_9

3. Significant Accounting Policies: Share Issuance Costs (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Share Issuance Costs	(h) Share Issuance Costs Professional, consulting, regulatory and other costs directly attributable to financing transactions are recorded as deferred financing costs until the financing transactions are completed, if the completion of the transaction is considered likely; otherwise they are expensed as incurred. Share issue costs are charged to share capital when the related shares are issued. Deferred financing costs related to financing transactions that are not completed are charged to expenses.

3. Significant Accounting Po_10

3. Significant Accounting Policies: Share Capital (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Share Capital	(i) Share Capital Instruments issued by the Company are classified as equity only to the extent that they do not meet the definition of a financial liability or financial asset. The Company's common and convertible preferred shares are classified as equity instruments. Incremental costs directly attributable to the issue of new shares are shown in equity as a deduction, net of tax, from the proceeds. The proceeds from issuance of units are allocated between shares and warrants based on the residual method. Under this method, the proceeds are allocated first to share capital based on the fair value of the shares at the time the units are issued and any residual value is allocated to warrant reserve.

3. Significant Accounting Po_11

3. Significant Accounting Policies: Adoption of New or Amended Accounting Standards (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
Adoption of New or Amended Accounting Standards	(j) Adoption of New or Amended Accounting Standards IFRS 9 Financial Instruments: Classification and Measurement - The Company adopted all of the requirements of IFRS 9 for the annual period beginning on August 1, 2019. IFRS 9 replaces IAS 39 Financial Instruments: Recognition and Measurement. IFRS 9 utilizes a revised model for recognition and measurement of financial instruments and a single, forward-looking “expected loss” impairment model. Most of the requirements in IAS 39 for classification and measurement of financial liabilities were carried forward in IFRS 9, so the Company’s accounting policy with respect to financial liabilities is unchanged. As a result of the adoption of IFRS 9, management has changed its accounting policy for financial assets retrospectively, for assets that continued to be recognized at the date of initial application. The change did not impact the carrying value of any financial assets or financial liabilities on the transition date. The following table shows the original classification under IAS 39 and the new classification under IFRS 9: Financial assets/liabilities Original classification IAS 39 New classification IFRS 9 Financial assets: Cash and cash equivalents FVTPL FVTPL Financial liabilities: Accounts payable Amortized cost Amortized cost Due to related parties Amortized cost Amortized cost Loans payable Amortized cost Amortized cost IFRS 15 Revenue from Contracts with Customers – IFRS 15 establishes a comprehensive framework for determining whether, how much and when revenue is recognized. It has replaced IAS 18 Revenue, IAS 11 Construction Contracts and related interpretations. The new standard establishes a five-step model to account for revenue arising from contracts with customers. Under IFRS 15, revenue is recognized at an amount that reflects the consideration to which an entity expects to be entitled in exchange for transferring goods or services to a customer. The Company has adopted the amendments to IFRS 15 in its financial statements for the annual period beginning on August 1, 2019 with no resulting adjustments. IFRS 2 Share-based Payment In November 2016, the IASB has revised IFRS 2 to incorporate amendments issued by the IASB in June 2016. The amendment provide guidance on the accounting for i) the effects of vesting and non-vesting conditions on the measurement of cash-settled share-based payments; ii) share-based payment transactions with a net settlement feature for withholding tax obligations and iii) a modification to the terms and conditions of a share-based payment that changes the classification of the transaction from cash-settled to equity-settled. The amendments are effective for annual periods beginning on or after January 1, 2018. Earlier application is permitted. The Company has adopted the amendments to IFRS 2 in its financial statements for the annual period beginning on August 1, 2019 with no resulting adjustments.

3. Significant Accounting Po_12

3. Significant Accounting Policies: New Accounting Standards Issued but Not Yet Effective (Policies)	12 Months Ended
	Jul. 31, 2019
Policies
New Accounting Standards Issued but Not Yet Effective	(k) New Accounting Standards Issued but Not Yet Effective New standards and interpretations not yet adopted Certain new standards, interpretations and amendments to existing standards have been issued by the IASB that are mandatory for future accounting periods with early adoption permitted. Some updates that are not applicable or are not consequential to the Company may have been excluded from the list below. Standard is effective for annual periods beginning on or after January 1, 2019: IFRS 16 Leases - The standard is effective for annual periods beginning on or after January 1, 2019. The Company is assessing the impact of this new standard on its consolidated financial statements.

2. Basis of Preparation and S_7

2. Basis of Preparation and Statement of Compliance: Basis of Consolidation: Schedule of Subsidiaries (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Subsidiaries	Entity Domicile of Incorporation % of interest at July 31, 2019 Royalty USA Corp. Delaware , USA 100% RLTY Beverage 1 LLC Delaware , USA 100% RLTY Development MA 1 LLC Delaware , USA 100% RLTY Development 1 NV 1 LLC Delaware , USA 100% RLTY Development Orange LLC Massachusetts , USA 100% RLTY Development Springfield LLC Massachusetts , USA 100% RLTY Service LLC Delaware , USA 100% RLTY Development FLA 1 LLC Delaware , USA 100% RLTY Development FLA 2 LLC Delaware , USA 100% RLTY Development CA 1 LLC Delaware , USA 100%

4. Prepaid Expenses and Depos_2

4. Prepaid Expenses and Deposits: Schedule of Prepaid Expenses and Deposits (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Prepaid Expenses and Deposits	July 31, 2019 $ July 31, 2018 $ Insurance 1,432 72,621 Advertising and promotion 71,736 89,894 Consulting 24,797 322,891 Deposits 31,453 46,453 129,418 531,859

6. Promissory Note Receivable_

6. Promissory Note Receivable: Schedule of Continuity (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Continuity	Total $ Balance, July 31, 2018 and 2017 - Funds advanced 3,216,274 Accrued interest 197,429 Foreign exchange (1,282) Balance, July 31, 2019 3,412,421

8. Investments in Equity Secu_2

8. Investments in Equity Securities: Schedule of Continuity (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Continuity	Fair value hierarchy level Level 1 Level 3 Level 2 Investments Measured at FVTPL Harborside Inc. Common Shares $ Harborside Inc. Warrants $ Lighthouse Strategies, LLC $ Total $ Balance, July 31, 2018 and 2017 - - - - Addition 3,571,614 536,697 6,574,000 10,682,311 Disposal (2,984,461) - - (2,984,461) Unrealized loss on changes in fair value - (451,970) (4,921,062) ( 5,373,032 Realized loss on changes in fair value (583,898) - - (583,898) Foreign exchange (3,255) (2,666) 31,954 26,033 Balance, July 31, 2019 - 82,061 1,684,892 1,776,953

9. Accounts Payable and Accru_2

9. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Accounts Payable and Accrued Liabilities	July 31, 2019 $ July 31, 2018 $ Accounts payables 304,540 235,357 Accrued liabilities 32,000 76,000 336,540 311,357

10. Related Party Transaction_2

10. Related Party Transactions and Balances: Schedule of Related Party Transactions (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Related Party Transactions	K ey management compensation for the years ended July 31, 2019 and 2018 is as follows: 2019 $ 2018 $ Short-term employee benefits: Consulting fees 195,164 463,602 Salary and benefits 476,763 180,420 671,927 644,022 Share-based compensation 1,403,282 1,651,395 Total 2,075,209 2,295,417

11. Share Capital_ Schedule of

11. Share Capital: Schedule of Continuity of Stock Options (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Continuity of Stock Options	Continuity of stock options outstanding during the year ended July 31, 2019 and 2019 are as follows: Options outstanding Weighted average exercise price $ Balance, July 31, 2017 - - Issued 16,468,727 0.33 Balance, July 31, 2018 16,468,727 0.33 Forfeited (15,010,000) (0.30) Issued 27,177,039 0.31 Balance, July 31, 2019 28,635,766 0.33

11. Share Capital_ Schedule o_2

11. Share Capital: Schedule of Outstanding and Exercisable Stock Options (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Outstanding and Exercisable Stock Options	Expiry Date Exercise price $ Number of options # Exercisable options # September 24, 2020 US $0.24 100,000 37,500 April 26, 2024 US $0.26 20,327,039 20,327,039 June 22, 2023 0.33 7,488,727 6,426,227 December 12, 2023 US $0.12 720,000 180,000 0.33 28,635,766 26,970,766

11. Share Capital_ Schedule o_3

11. Share Capital: Schedule of Continuity of Common Share Purchase Warrants (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Continuity of Common Share Purchase Warrants	Number of share purchase warrants # Weighted average exercise price $ Outstanding, July 31, 2017 - - Issued 130,721,365 0.06 Exercised (5,050,000) 0.05 Outstanding, July 31, 2018 125,671,365 0.06 Issued 17,910,000 0.05 Exercised (17,810,000) 0.05 Outstanding, July 31, 2019 125,771,365 0.06

11. Share Capital_ Schedule o_4

11. Share Capital: Schedule of Share Purchase Warrants Outstanding and Exercisable (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Share Purchase Warrants Outstanding and Exercisable	Expiry Date Exercise price $ Number of warrants # February 8, 2020 0.05 57,607,000 March 1, 2020 0.05 47,512,000 April 30, 2020 0.05 15,470,000 June 11, 2020 0.33 5,182,365 125,771,365

12. Financial Instruments and_2

12. Financial Instruments and Risks: Schedule of Fair Values and Classification of Financial Instruments (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Fair Values and Classification of Financial Instruments	Financial Instrument Category July 31 , 2019 July 31 , 2018 Cash and cash equivalents FVTPL $ 2,961,514 $ 33,904,759 Convertible debenture receivable FVTPL 15,000,000 - Promissory note receivable FVTPL 3,412,421 - Investments in equity securities FVTPL 1,766,953 - Accounts payable Amortized cost 304,540 235,357 Due to related parties Amortized cost 21,347 18,685 Loans payable Amortized cost - 10,000

12. Financial Instruments and_3

12. Financial Instruments and Risks: Schedule of Financial Assets measured on a recurring basis at fair value (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Financial Assets measured on a recurring basis at fair value	July 31, 2019 Level 1 Level 2 Level 3 Total Cash and cash equivalents $ 2,961,514 $ - $ - $ 2,961,514 Convertible debenture receivable - - 15,000,000 15,000,000 Promissory note receivable - 3,412,421 - 3,412,421 Investments in membership units - 1,684,892 - 1,684,892 Investments in warrants - - 82,061 82,061 July 31, 2018 Level 1 Level 2 Level 3 Total Cash $ 33,904,759 $ - $ - $ 33,904,759

12. Financial Instruments and_4

12. Financial Instruments and Risks: Schedule of Changes in Level 3 Items (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Changes in Level 3 Items	Convertible debenture receivable Investments in warrants Balance, July 31, 2018 and 2017 $ - $ - Additions 17,492,303 536,697 Conversion of debenture (3,365,556) - Unrealized loss on changes in fair value - (451,970) Realized gain on changes in fair value 865,790 Foreign exchange 7,463 (2,666) Balance, July 31, 2019 $ 15,000,000 $ 82,061

12. Financial Instruments and_5

12. Financial Instruments and Risks: Schedule of Foreign Currency Risk (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Foreign Currency Risk	July 31, 2019 July 31, 2018 Balance in US dollars: Cash and cash equivalents $ - $ 15,126,020 Prepaid expenses and deposits 250,000 Promissory note receivable 2,595,392 - Accounts payable - (46,138) Net exposure 2,845,392 $ 15,079,882 Balance in Canadian dollars: $ 3,741,121 $ 19,629,482

12. Financial Instruments and_6

12. Financial Instruments and Risks: Schedule of contractual maturities of financial liabilities (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of contractual maturities of financial liabilities	The following are contractual maturities of financial liabilities as at July 31, 2019: Carrying amount Contractual cash flows Within 1 year Accounts payable and accrued liabilities $ 336,540 $ 336,540 $ 336,540 Due to related parties 21,347 21,347 21,347 The following are contractual maturities of financial liabilities as at July 31, 2018: Carrying amount Contractual cash flows Within 1 year Accounts payable and accrued liabilities $ 311,357 $ 311,357 $ 311,357 Due to related parties 18,685 18,685 18,685 Loans payable 10,000 10,000 10,000

13. Income Taxes_ Schedule of C

13. Income Taxes: Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	2019 $ 2018 $ Net loss before income taxes (18,611,721) (7,825,089) Canadian statutory income tax rate 27.00% 26.50% Expected income tax recovery at statutory rate 5,025,165 2,073,649 Tax effect of: Other non-deductible expense 2,095,667 (96,209) Difference between income tax rates (303,226) - Change in tax rate - 20,314 Change in unrecognized deferred tax assets (6,817,606) (1,997,754) Income tax recovery - -

13. Income Taxes_ Schedule of D

13. Income Taxes: Schedule of Deferred Tax Assets and Liabilities [Table Text Block] (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	2019 $ 2018 $ Deferred income tax assets: Non-capital losses carried forward 7,583,620 1,753,878 Resource pools 694,023 681,172 Investment in equity securities 1,121,010 - Share issuance costs 473,032 619,029 Total gross deferred income tax assets 9,871,685 3,054,079 Unrecognized deferred tax assets (9,871,685) (3,054,079) Net deferred income tax assets - -

13. Income Taxes_ Schedule of E

13. Income Taxes: Schedule of Expiration of Non-capital losses (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Expiration of Non-capital losses	$ 2030 300 2031 96,900 2032 139,400 2033 225,600 2034 18,300 2035 122,000 2036 60,000 2037 32,500 2038 5,125,000 2039 22,268,000 28,088,000

15. Segment Information_ Schedu

15. Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Segment Reporting Information, by Segment	Canada United States of America Total Non-current assets other than financial instruments $ - $ 592,655 $ 592,655

16. Commitments_ Schedule of Fu

16. Commitments: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)	12 Months Ended
	Jul. 31, 2019
Tables/Schedules
Schedule of Future Minimum Rental Payments for Operating Leases	$ 2020 294,205 2021 49,034 343,239

1. Nature and Continuance of _2

1. Nature and Continuance of Operations (Details) - CAD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Details
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line Two	Suite 810
Entity Address, Address Line One	789 West Pender Street
Entity Address, City or Town	Vancouver
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V6C 1H2
Accumulated deficit	$ (38,897,040)	$ (20,285,319)

2. Basis of Preparation and S_8

2. Basis of Preparation and Statement of Compliance: Basis of Consolidation: Schedule of Subsidiaries (Details)	12 Months Ended
	Jul. 31, 2019
Royalty USA Corp
Entity Incorporation, State or Country Code	DE
Entity Incorporation, State or Country Code	A1
Ownership Interest	100.00%
RLTY Beverage 1 LLC
Entity Incorporation, State or Country Code	DE
RLTY Development MA 1 LLC
Entity Incorporation, State or Country Code	DE
RLTY Development 1 NV 1 LLC
Entity Incorporation, State or Country Code	DE
RLTY Development Orange LLC
Entity Incorporation, State or Country Code	MA
RLTY Development Springfield LLC
Entity Incorporation, State or Country Code	MA
RLTY Service LLC
Entity Incorporation, State or Country Code	DE
RLTY Development FLA 1 LLC
Entity Incorporation, State or Country Code	DE
RLTY Development FLA 2 LLC
Entity Incorporation, State or Country Code	DE
RLTY Development CA 1 LLC
Entity Incorporation, State or Country Code	DE

4. Prepaid Expenses and Depos_3

4. Prepaid Expenses and Deposits: Schedule of Prepaid Expenses and Deposits (Details) - CAD ($)		Jul. 31, 2019	Jul. 31, 2018
Prepaid expenses and deposits	[1]	$ 129,418	$ 531,859
[1]	See Note 4.

5. Convertible Debenture Rece_2

5. Convertible Debenture Receivable (Details)	12 Months Ended
	Jul. 31, 2019CAD ($)$ / shares
Convertible Debenture Receivable #1
Debt Instrument, Issuer	MichiCann Medical Inc.
Debt Instrument, Face Amount | $	$ 15,000,000
Debt Instrument, Description	senior secured convertible debenture
Debt Instrument, Interest Rate, Stated Percentage	0.00%
Debt Instrument, Maturity Date	Oct. 25, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used	Black- Scholes option pricing and discounted cash flow models
Share Price	$ 2.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 2.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.65%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	52.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	25 days
Convertible Debenture Receivable #2
Debt Instrument, Issuer	Harborside Inc.
Debt Instrument, Face Amount | $	$ 3,029,000
Debt Instrument, Description	senior unsecured convertible debenture units
Debt Instrument, Interest Rate, Stated Percentage	12.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used	Black- Scholes option pricing and discounted cash flow models
Share Price	$ 5.95
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 6.90
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.91%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	81.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 months 11 days

6. Promissory Note Receivable (

6. Promissory Note Receivable (Details) - CAD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Promissory Note Receivable #1
Debt Instrument, Description	promissory note agreement
Debt Instrument, Face Amount	$ 3,216,274
Long-term Debt	$ 3,216,274	$ 0
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Maturity Date	Feb. 28, 2021
Promissory Note Receivable #2
Debt Instrument, Description	two promissory notes
Debt Instrument, Interest Rate, Stated Percentage	10.00%
Debt Instrument, Maturity Date	Aug. 31, 2021
Debt Instrument, Issuance Date	Aug. 23, 2019
Promissory Note Receivable #3
Debt Instrument, Description	definitive Membership Interest Purchase Agreement
Debt Instrument, Issuance Date	Sep. 26, 2019

6. Promissory Note Receivable_2

6. Promissory Note Receivable: Schedule of Continuity (Details) - CAD ($)	12 Months Ended
	Jul. 31, 2019		Jul. 31, 2018	[1]	Jul. 31, 2017
Details
Promissory note receivable	$ 3,412,421	[1]	$ 0		$ 0
Funds advanced	3,216,274
Accrued interest	197,429
Foreign exchange	$ (1,282)
[1]	See Note 6.

8. Investments in Equity Secu_3

8. Investments in Equity Securities: Schedule of Continuity (Details)	12 Months Ended
	Jul. 31, 2019CAD ($)
Investment Owned, at Fair Value, Starting Balance	$ 0
Addition	10,682,311
Disposal	(2,984,461)
Unrealized loss on changes in fair value	(5,373,032)
Realized loss on changes in fair value	(583,898)
Foreign exchange	26,033
Investment Owned, at Fair Value, Ending Balance	1,776,953
Fair Value, Inputs, Level 1
Investment Owned, at Fair Value, Starting Balance	0
Addition	3,571,614
Disposal	(2,984,461)
Unrealized loss on changes in fair value	0
Realized loss on changes in fair value	(583,898)
Foreign exchange	(3,255)
Investment Owned, at Fair Value, Ending Balance	0
Fair Value, Inputs, Level 2
Investment Owned, at Fair Value, Starting Balance	0
Addition	536,697
Disposal	0
Unrealized loss on changes in fair value	(451,970)
Realized loss on changes in fair value	0
Foreign exchange	(2,666)
Investment Owned, at Fair Value, Ending Balance	82,061
Fair Value, Inputs, Level 3
Investment Owned, at Fair Value, Starting Balance	0
Addition	6,574,000
Disposal	0
Unrealized loss on changes in fair value	(4,921,062)
Realized loss on changes in fair value	0
Foreign exchange	31,954
Investment Owned, at Fair Value, Ending Balance	$ 1,684,892

8. Investments in Equity Secu_4

8. Investments in Equity Securities (Details)	12 Months Ended
	Jul. 31, 2019CAD ($)shares
Harborside Inc. Common Shares
Stock Issued During Period, Shares, New Issues | shares	567,205
Stock Issued	$ 2,984,461
Foreign exchange loss	3,255
Realized loss on changes in fair value of investments in equity securities	583,898
Harborside Inc. Warrants
Unrealized loss on investments in equity securities	451,970
Lighthouse Strategies, LLC
Unrealized loss on investments in equity securities	$ 4,921,062

9. Accounts Payable and Accru_3

9. Accounts Payable and Accrued Liabilities: Schedule of Accounts Payable and Accrued Liabilities (Details) - CAD ($)		Jul. 31, 2019	Jul. 31, 2018
Details
Accounts payables		$ 304,540	$ 235,357
Accrued liabilities		32,000	76,000
Accounts payable and accrued liabilities	[1]	$ 336,540	$ 311,357
[1]	See Note 9.

10. Related Party Transaction_3

10. Related Party Transactions and Balances: Schedule of Related Party Transactions (Details) - CAD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Short-term employee benefits:
Consulting fees	$ 195,164	$ 463,602
Salary and benefits	476,763	180,420
Short-term employee benefits	671,927	644,022
Share-based compensation	1,403,282	1,651,395
Total	$ 2,075,209	$ 2,295,417

10. Related Party Transaction_4

10. Related Party Transactions and Balances (Details) - CAD ($)		12 Months Ended
		Jul. 31, 2019	Jul. 31, 2018
Details
Rent paid to related parties		$ 4,000	$ 9,100
Due to related parties	[1]	$ 21,347	$ 18,685
[1]	See Note 10.

11. Share Capital (Details)

11. Share Capital (Details)		12 Months Ended
		Jul. 31, 2019CAD ($)$ / sharesshares	Jul. 31, 2018CAD ($)$ / sharesshares	Jul. 31, 2017shares
Share-based compensation | $	[1]	$ 7,329,800	$ 3,250,476
Convertible Preferred Shares, #1
Preferred Stock, Shares Issued		40,000,000
Preferred shares issuable reclassified | $		$ 2,000,000
Preferred shares converted to Common shares		29,100,000
Preferred shares reclassified to Common shares | $		$ 1,365,780
Convertible Preferred Shares, #2
Sale of Stock, Transaction Date			May 25, 2018
Preferred Units, Issued			40,000,000
Sale of Stock, Price Per Share | $ / shares			$ 0.05
Stock Issued | $			$ 2,000,000
Common Shares, #1
Stock Issued | $		$ 890,500
Stock Issued During Period, Shares, New Issues		17,810,000
Common Shares, #2
Sale of Stock, Transaction Date		Sep. 26, 2018
Stock Issued | $		$ 141,440
Sale of Stock, Description of Transaction		4,000,000 special finder’s warrants issued on May 25, 2018 with a carrying value of $141,440 were converted into an equivalent number of units in the capital of the Company
Common Shares, #3
Sale of Stock, Transaction Date		Aug. 31, 2018
Stock Issued | $		$ 695,500
Sale of Stock, Description of Transaction		2,690,000 special warrants and 1,220,000 special finders’ warrants issued on April 26, 2018 with a carrying value of $ 695,500 were converted into an equivalent number of units in the capital of the Company
Common Shares, #4
Sale of Stock, Transaction Date			Jun. 8, 2018
Stock Issued | $			$ 3,156,350
Sale of Stock, Description of Transaction			Company converted 59,370,000 special warrants and 3,757,000 special finders’ warrants issued on February 8, 2018 into an equivalent number of units in the capital of the Company
Common Shares, #5
Sale of Stock, Transaction Date			Jun. 12, 2018
Sale of Stock, Price Per Share | $ / shares			$ 0.33
Stock Issued | $			$ 31,137,159
Sale of Stock, Description of Transaction			Company issued 94,355,026 common shares
Cash commission | $			$ 2,067,500
Other legal and finder's fees | $			64,000
Common Shares, #5a
Stock Issued | $			5,182,365
Finder's warrants granted, fair value | $			$ 1,209,136
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used			Black Scholes Option Pricing Model
Share Price | $ / shares			$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares			$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			2 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			147.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.90%
Common Shares, #6
Stock Issued | $			$ 252,500
Sale of Stock, Description of Transaction			Company issued 5,050,000 common shares
Common Shares, #7
Sale of Stock, Transaction Date			Jul. 1, 2018
Stock Issued | $			$ 2,856,000
Sale of Stock, Description of Transaction			Company converted 57,120,000 special warrants and 5,292,000 special finders’ warrants issued on March 1, 2018 into an equivalent number of units in the capital of the Company
Stock Options, #1
Sale of Stock, Description of Transaction		August 16, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used		Black-Scholes Option Pricing Model
Share Price | $ / shares		$ 0.74
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares		$ 0.73
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		147.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.18%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares		$ 0.73
Stock Option term in years		5
Share-based compensation | $		$ 145,052
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		1,000,000
Stock Options, #2
Sale of Stock, Description of Transaction		September 24, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used		Black-Scholes Option Pricing Model
Share Price | $ / shares		$ 0.31
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares		$ 0.31
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		2 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		147.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.13%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares		$ 0.31
Stock Option term in years		2
Share-based compensation | $		$ 12,274
Stock Options, #3
Sale of Stock, Description of Transaction		December 12, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used		Black-Scholes Option Pricing Model
Share Price | $ / shares		$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares		$ 0.15
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		147.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.07%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		5,750,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares		$ 0.15
Stock Option term in years		5
Share-based compensation | $		$ 151,349
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		5,030,000
Stock Options, #4
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used		Black-Scholes Option Pricing Model
Share Price | $ / shares		$ 0.34
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares		$ 0.34
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		147.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.52%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		20,327,039
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares		$ 0.34
Stock Option term in years		5
Share-based compensation | $		$ 6,426,936
Stock Options, #5
Sale of Stock, Description of Transaction			June 22, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used			Black-Scholes Option Pricing Model
Share Price | $ / shares			$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares			$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term			5 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate			147.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate			0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			1.98%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures			16,468,727
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | $ / shares			$ 0.33
Stock Option term in years			5
Share-based compensation | $		$ 594,189	$ 3,250,476
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period		8,980,000
Special Warrants, #1
Sale of Stock, Transaction Date		Feb. 8, 2018
Sale of Stock, Price Per Share | $ / shares		$ 0.05
Stock Issued | $		$ 2,968,500
Stock Issued During Period, Shares, New Issues		59,370,000
Sale of Stock, Description of Transaction		non-brokered private placement, of 59,370,000 special warrants
Special Warrants, #2
Sale of Stock, Transaction Date		Jun. 8, 2018
Stock Issued | $		$ 187,850
Stock Issued During Period, Shares, New Issues		3,757,000
Sale of Stock, Description of Transaction		Company converted the special warrants and special finders’ warrants into an equivalent number of units in the capital of the Company
Special Warrants, #3
Sale of Stock, Transaction Date		Mar. 1, 2018
Sale of Stock, Price Per Share | $ / shares		$ 0.05
Stock Issued | $		$ 2,856,000
Stock Issued During Period, Shares, New Issues		57,120,000
Sale of Stock, Description of Transaction		non-brokered private placement, of 57,120,000 special warrants
Special Warrants, #4
Sale of Stock, Transaction Date		Jul. 1, 2018
Stock Issued | $		$ 264,600
Stock Issued During Period, Shares, New Issues		5,292,000
Sale of Stock, Description of Transaction		Company converted the special warrants and special finders’ warrants into an equivalent number of units in the capital of the Company
Special Warrants, #5
Sale of Stock, Transaction Date		Apr. 30, 2018
Sale of Stock, Price Per Share | $ / shares		$ 0.05
Stock Issued | $		$ 634,500
Stock Issued During Period, Shares, New Issues		12,690,000
Sale of Stock, Description of Transaction		non-brokered private placement, of 12,690,000 special warrants
Special Warrants, #6
Sale of Stock, Transaction Date		Aug. 31, 2018
Stock Issued | $		$ 61,000
Stock Issued During Period, Shares, New Issues		1,220,000
Sale of Stock, Description of Transaction		Company converted the special warrants and special finders’ warrants into an equivalent number of units in the capital of the Company
special warrants and special finders' warrants outstanding			13,910,000
Reclassification of warrants to reserve			695,500
Special Warrants, #7
Sale of Stock, Transaction Date		May 25, 2018
Stock Issued | $		$ 141,440
Stock Issued During Period, Shares, New Issues		4,000,000
Sale of Stock, Description of Transaction		granted 4,000,000 special finders’ warrants as finder’s fees
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used		Black Scholes Option Pricing Model
Share Price | $ / shares		$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | $ / shares		$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		2 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		147.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.96%
Reclassification of warrants to reserve			141,440
Special finders' warrants outstanding			4,000,000
Special Warrants, #8
Sale of Stock, Transaction Date		Sep. 26, 2018
Sale of Stock, Description of Transaction		Company converted the special finders’ warrants into an equivalent number of units in the capital of the Company
Convertible preferred shares
Shares, Outstanding		50,900,000	40,000,000	0
Stock Issued During Period, Shares, New Issues		40,000,000	40,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		0	0
Common Stock
Shares, Outstanding		292,607,662	227,787,662	2,843,636
Stock Issued During Period, Shares, New Issues		0	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures		0	0
[1]	See Notes 10 and 11.

11. Share Capital_ Schedule o_5

11. Share Capital: Schedule of Continuity of Stock Options (Details) - Stock Options - $ / shares	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	16,468,727	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 0.33	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	27,177,039	16,468,727
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.31	$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	28,635,766	16,468,727
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 0.33	$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period	(15,010,000)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price	$ (0.30)

11. Share Capital_ Schedule o_6

11. Share Capital: Schedule of Outstanding and Exercisable Stock Options (Details)	Jul. 31, 2019$ / sharesshares	Jul. 31, 2018$ / shares
Stock Options - Expiry Date September 24, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares		$ 0.24
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	37,500
Stock Options - Expiry Date April 26, 2024
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares		0.26
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	20,327,039
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	20,327,039
Stock Options - Expiry Date June 22, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	7,488,727
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	6,426,227
Stock Options - Expiry Date December 12, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares		$ 0.12
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	720,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	180,000
Stock Options - Expiry Date All
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	28,635,766
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number	26,970,766

11. Share Capital_ Schedule o_7

11. Share Capital: Schedule of Continuity of Common Share Purchase Warrants (Details) - Common Share Purchase Warrants - $ / shares	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	125,671,365	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 0.06	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	17,910,000	130,721,365
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0.05	$ 0.06
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	(17,810,000)	(5,050,000)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price	$ 0.05	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	125,771,365	125,671,365
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 0.06	$ 0.06

11. Share Capital_ Schedule o_8

11. Share Capital: Schedule of Share Purchase Warrants Outstanding and Exercisable (Details)	Jul. 31, 2019$ / sharesshares
Common Share Purchase Warrants - Expiry Date February 8, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	57,607,000
Common Share Purchase Warrants - Expiry Date March 1, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	47,512,000
Common Share Purchase Warrants - Expiry Date April 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	15,470,000
Common Share Purchase Warrants - Expiry Date June 11, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ / shares	$ 0.33
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	5,182,365
Common Share Purchase Warrants - Expiry Date All
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number	125,771,365

12. Financial Instruments and_7

12. Financial Instruments and Risks: Schedule of Fair Values and Classification of Financial Instruments (Details) - CAD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Cash and cash equivalents
Category	FVTPL
Fair Value of Financial Instruments	$ 2,961,514	$ 33,904,759
Convertible debenture receivable
Category	FVTPL
Fair Value of Financial Instruments	$ 15,000,000	0
Promissory note receivable
Category	FVTPL
Fair Value of Financial Instruments	$ 3,412,421	0
Investments in equity securities
Category	FVTPL
Fair Value of Financial Instruments	$ 1,766,953	0
Accounts payable
Category	Amortized cost
Fair Value of Financial Instruments	$ 304,540	235,357
Due to related parties
Category	Amortized cost
Fair Value of Financial Instruments	$ 21,347	18,685
Loans payable
Category	Amortized cost
Fair Value of Financial Instruments	$ 0	$ 10,000

12. Financial Instruments and_8

12. Financial Instruments and Risks: Schedule of Financial Assets measured on a recurring basis at fair value (Details)	Jul. 31, 2019CAD ($)
Cash and cash equivalents
Assets, Fair Value Disclosure	$ 2,961,514
Convertible debenture receivable
Assets, Fair Value Disclosure	15,000,000
Promissory note receivable
Assets, Fair Value Disclosure	3,412,421
Investments in membership units
Assets, Fair Value Disclosure	1,684,892
Investments in warrants
Assets, Fair Value Disclosure	82,061
Cash
Assets, Fair Value Disclosure	33,904,759
Fair Value, Inputs, Level 1 | Cash and cash equivalents
Assets, Fair Value Disclosure	2,961,514
Fair Value, Inputs, Level 1 | Convertible debenture receivable
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 1 | Promissory note receivable
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 1 | Investments in membership units
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 1 | Investments in warrants
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 1 | Cash
Assets, Fair Value Disclosure	33,904,759
Fair Value, Inputs, Level 2 | Cash and cash equivalents
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 | Convertible debenture receivable
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 | Promissory note receivable
Assets, Fair Value Disclosure	3,412,421
Fair Value, Inputs, Level 2 | Investments in membership units
Assets, Fair Value Disclosure	1,684,892
Fair Value, Inputs, Level 2 | Investments in warrants
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 2 | Cash
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 | Cash and cash equivalents
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 | Convertible debenture receivable
Assets, Fair Value Disclosure	15,000,000
Fair Value, Inputs, Level 3 | Promissory note receivable
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 | Investments in membership units
Assets, Fair Value Disclosure	0
Fair Value, Inputs, Level 3 | Investments in warrants
Assets, Fair Value Disclosure	82,061
Fair Value, Inputs, Level 3 | Cash
Assets, Fair Value Disclosure	$ 0

12. Financial Instruments and_9

12. Financial Instruments and Risks: Schedule of Changes in Level 3 Items (Details)	12 Months Ended
	Jul. 31, 2019CAD ($)
Convertible debenture receivable
Assets, Changes in Level 3 items, Starting Balance	$ 0
Assets, Changes in Level 3 items - Additions	17,492,303
Assets, Changes in Level 3 items - Conversion of debenture	(3,365,556)
Assets, Changes in Level 3 items - Unrealized loss on changes in fair value	0
Assets, Changes in Level 3 items - Realized gain on changes in fair value	865,790
Assets, Changes in Level 3 items - Foreign exchange	7,463
Assets, Changes in Level 3 items, Ending Balance	15,000,000
Investments in warrants
Assets, Changes in Level 3 items, Starting Balance	0
Assets, Changes in Level 3 items - Additions	536,697
Assets, Changes in Level 3 items - Conversion of debenture	0
Assets, Changes in Level 3 items - Unrealized loss on changes in fair value	(451,970)
Assets, Changes in Level 3 items - Foreign exchange	(2,666)
Assets, Changes in Level 3 items, Ending Balance	$ 82,061

12. Financial Instruments an_10

12. Financial Instruments and Risks: Schedule of Foreign Currency Risk (Details)	Jul. 31, 2019USD ($)	Jul. 31, 2019CAD ($)	Jul. 31, 2018USD ($)	Jul. 31, 2018CAD ($)
Details
Foreign Currency Risk (USD) - Cash and cash equivalents	$ 0		$ 15,126,020
Foreign Currency Risk (USD) - Prepaid expenses and deposits	250,000
Foreign Currency Risk (USD) - Promissory note receivable	2,595,392		0
Foreign Currency Risk (USD) - Accounts payable	0		(46,138)
Foreign Currency Risk (USD) - Net exposure	$ 2,845,392		$ 15,079,882
Foreign Currency Risk (CAD)		$ 3,741,121		$ 19,629,482

12. Financial Instruments an_11

12. Financial Instruments and Risks: Schedule of contractual maturities of financial liabilities (Details) - CAD ($)	Jul. 31, 2019	Jul. 31, 2018
Accounts payable and accrued liabilities
Contractual Maturities of Financial Liabilities - Carrying amount	$ 336,540	$ 311,357
Contractual Maturities of Financial Liabilities - Contractual cash flows	336,540	311,357
Contractual Maturities of Financial Liabilities - Within 1 year	336,540	311,357
Due to related parties
Contractual Maturities of Financial Liabilities - Carrying amount	21,347	18,685
Contractual Maturities of Financial Liabilities - Contractual cash flows	21,347	18,685
Contractual Maturities of Financial Liabilities - Within 1 year	$ 21,347	18,685
Loans payable
Contractual Maturities of Financial Liabilities - Carrying amount		10,000
Contractual Maturities of Financial Liabilities - Contractual cash flows		10,000
Contractual Maturities of Financial Liabilities - Within 1 year		$ 10,000

13. Income Taxes_ Schedule of_2

13. Income Taxes: Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] (Details) - CAD ($)	12 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Details
Net loss before income taxes	$ (18,611,721)	$ (7,825,089)
Federal Statutory Rate	27.00%	26.50%
Expected income tax recovery at statutory rate	$ 5,025,165	$ 2,073,649
Tax effect of Other non-deductible expense	2,095,667	(96,209)
Tax effect of Difference between income tax rates	(303,226)	0
Tax effect of Change in tax rate	0	20,314
Tax effect of Change in unrecognized deferred tax assets	(6,817,606)	(1,997,754)
Income tax recovery	$ 0	$ 0

13. Income Taxes_ Schedule of_3

13. Income Taxes: Schedule of Deferred Tax Assets and Liabilities [Table Text Block] (Details) - CAD ($)	Jul. 31, 2019	Jul. 31, 2018
Details
Deferred Income Tax Assets - Non-capital losses carried forward	$ 7,583,620	$ 1,753,878
Deferred Income Tax Assets - Resource pools	694,023	681,172
Deferred Income Tax Assets - Investment in equity securities	1,121,010	0
Deferred Income Tax Assets - Share issuance costs	473,032	619,029
Total gross deferred income tax assets	9,871,685	3,054,079
Unrecognized deferred tax assets	(9,871,685)	(3,054,079)
Net deferred income tax assets	$ 0	$ 0

13. Income Taxes_ Schedule of_4

13. Income Taxes: Schedule of Expiration of Non-capital losses (Details)	Jul. 31, 2019CAD ($)
Non-capital losses carried forward	$ 28,088,000
Loss Carryforward - Expiration in 2030
Non-capital losses carried forward	300
Loss Carryforward - Expiration in 2031
Non-capital losses carried forward	96,900
Loss Carryforward - Expiration in 2032
Non-capital losses carried forward	139,400
Loss Carryforward - Expiration in 2033
Non-capital losses carried forward	225,600
Loss Carryforward - Expiration in 2034
Non-capital losses carried forward	18,300
Loss Carryforward - Expiration in 2035
Non-capital losses carried forward	122,000
Loss Carryforward - Expiration in 2036
Non-capital losses carried forward	60,000
Loss Carryforward - Expiration in 2037
Non-capital losses carried forward	32,500
Loss Carryforward - Expiration in 2038
Non-capital losses carried forward	5,125,000
Loss Carryforward - Expiration in 2039
Non-capital losses carried forward	$ 22,268,000

15. Segment Information_ Sche_2

15. Segment Information: Schedule of Segment Reporting Information, by Segment (Details)	Jul. 31, 2019CAD ($)
Non-current assets other than financial instruments	$ 592,655
CANADA
Non-current assets other than financial instruments	0
UNITED STATES
Non-current assets other than financial instruments	$ 592,655

16. Commitments_ Schedule of _2

16. Commitments: Schedule of Future Minimum Rental Payments for Operating Leases (Details)	Jul. 31, 2019CAD ($)
Details
2020	$ 294,205
2021	49,034
Operating Lease, Liability	$ 343,239

17. Subsequent Events (Details)

17. Subsequent Events (Details)	12 Months Ended
	Jul. 31, 2019CAD ($)shares
Event #1
Subsequent Event, Description	Company issued 9,165,000 common shares
Stock Issued During Period, Shares, New Issues | shares	9,165,000
Sale of Stock, Description of Transaction	pursuant to warrant exercises
Stock Issued | $	$ 458,250
Event #2
Subsequent Event, Description	Company entered into a definitive Membership Interest Purchase Agreement	[1]
[1]	See Note 6.